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ABSTRACT 
 
Although non-steroidal anti-inflammatory drugs (NSAIDs) are among the most 
frequently used classes of medications in the world, they are well-known to induce an 
enteropathy that is associated with high morbidity and mortality in upwards of 70% of 
users. The diagnosis of NSAID enteropathy is difficult. Furthermore, the underlying 
mechanisms by which NSAIDs induce enteropathy remain ill-defined although 
microbiota-host interactions appear to play an important role. Importantly, in addition to 
difficulty in diagnosing this disease, there are also no effective treatment strategies. 
Therefore, the purpose of this research was to determine if the microbiota-derived 
metabolite indole, could attenuate severity of NSAID enteropathy. A second goal was to 
determine if the transcriptome of exfoliated intestinal epithelial cells (IECs) found in the 
stool could be reflective of NSAID enteropathy, thereby allowing a non-invasive 
approach to studying how the mucosal transcriptome is altered by NSAIDs and 
potentially discriminating between healthy and diseased animals.  
We utilized a mouse model of NSAID enteropathy, whereby mice were assigned 
to 1 of 4 groups: 1) NSAID; 2) indole; 3) NSAID + indole; and, 4) untreated controls. 
Disease severity was determined by a number of assays including: fecal calprotectin, 
microscopic pathology, neutrophil infiltration, and RNA-seq of the ileal mucosa. 
Diversity and composition of the fecal microbiota was determined by 16S rRNA 
sequencing. Non-invasive examination of the mucosal transcriptome was determined by 
isolation and sequencing of polyA+ RNA from the stool followed by novel 
 iii 
 
computational approaches to assess the inter-relatedness of exfoliated and tissue-level 
transcriptomes. 
Results from these assays revealed that indole did in fact attenuate disease 
severity and this improvement appeared to be related to composition of the microbiota. 
In addition, approximately 96% of all genes that were mapped from the exfoliated cell 
RNA were also present in the tissue-level RNA and the pathways represented by these 
genes and their directional changes were similar in both the small intestinal mucosa and 
exfoliated IEC transcriptome. These findings demonstrate that the exfoliated cell 
transcriptome correlates to the tissue-level transcriptome and can be used to gain 
longitudinal information related to NSAID-induced alterations of the mucosal 
transcriptome and to discriminate between diseased and healthy animals.  
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CHAPTER I 
INTRODUCTION TO NON-STEROIDAL ANTI-INFLAMMATORY DRUG (NSAID) 
ENTEROPATHY WITH A FOCUS ON HOW THE GUT MICROBIOTA 
CONTRIBUTES TO THE DEVELOPMENT OF DISEASE   
 
Introduction 
Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most widely used 
class of medications in the world. These drugs are used daily by many millions of people 
to treat a host of inflammatory and painful conditions as well as for their anti-neoplastic 
affects. This class of medications, however, has several adverse effects of which 
ulceration and bleeding of the gastrointestinal (GI) tract are most common. Damage by 
NSAIDs occurs in 2 locations of the GI tract: 1) the upper GI tract involving the stomach 
and duodenum (termed NSAID gastropathy); and, 2) the lower GI tract, most commonly 
the distal small intestine in people (termed NSAID enteropathy). While NSAID-induced 
gastropathy remains a clinical concern, accurate diagnostic tests and effective 
management strategies exist. In contrast, NSAID enteropathy is difficult to diagnose and 
there are no effective management strategies, despite the fact that it occurs as or more 
frequently than NSAID-induced gastropathy. In fact, NSAID enteropathy affects up to 
70% of people that use NSAIDs including short-term users.[1, 2]  
The pathophysiology of NSAID enteropathy remains complex and ill-defined. 
The current paradigm for the pathophysiology of NSAID enteropathy involves a multi-
step process whereby NSAIDs initially induce topical injury to the intestinal epithelial 
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cells (IECs) comprising the intestinal mucosa. This results in impaired intestinal barrier 
function resulting in invasion of intestinal bacteria and other luminal contents (e.g., 
lipopolysaccharide [LPS], bile acids). The deeper layers of the bowel wall (i.e., the 
lamina propria) are laden with immune cells that respond to defects in barrier function 
resulting in profound inflammation.  Finally, healing is impaired due to decreased 
protective mucosal prostaglandins resulting from cyclooxygenase (COX) inhibition.  
Although the steps described in this multi-hit theory are clearly important, there 
are aspects of NSAID enteropathy that are not adequately explained by this process. 
Increasing evidence indicates that interaction of NSAIDs with the gut microbiota 
contribute to the development of NSAID enteropathy.  The purpose of this report is to 
review the pathophysiology of NSAID enteropathy with emphasis on interactions 
between NSAIDs, the host GI tract, and the gut microbiota and potential mechanisms by 
which the microbiota alters the severity of NSAID-induced intestinal injury.  As 
described here, the gut microbiota plays a pivotal role in multiple aspects of the 
pathogenesis of NSAID enteropathy. 
Canonical Pathogenesis of NSAID Enteropathy 
Topical Effects of NSAIDs on IECs 
It is well established that topical effects of NSAIDs on IECs are among the 
earliest events of NSAID-induced intestinal injury.[3, 4] The exact concentrations of 
orally administered NSAIDs in the lumen of the GI tract are unknown; however, biliary 
concentrations of NSAIDs have been shown to be much higher (i.e., low millimolar 
range) than plasma concentrations (i.e., low micromolar range), suggesting that  
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intestinal luminal concentrations are higher than those in bile.[5, 6] Thus, the membranes 
of IECs (enterocytes) are bathed in relatively high concentrations of NSAIDs when these 
drugs are administered. The NSAIDs and their metabolites have profound effects on IEC 
membranes including altering their hydrophobicity, fluidity, and biomechanical 
properties, which increase the permeability of IECs to luminal contents, including 
NSAID metabolites.[7] Additionally, NSAIDs are almost all weak organic acids that are 
lipophilic and thus may easily enter the cell membrane (especially at low pH), even in 
the absence of IEC membrane damage.  
Once NSAIDs enter the enterocyte, the first intracellular organelles to become 
affected are the mitochondria and the endoplasmic reticulum (ER).[8, 9] These effects of 
NSAIDs on these organelles occur rapidly, perhaps within 1 hour.[4] NSAIDs induce 
ER stress due to an accumulation of misfolded proteins which leads to accumulation of 
intracellular calcium and apoptosis.[9] In the mitochondria, NSAIDs uncouple oxidative 
phosphorylation which also leads eventually to cell death via apoptosis.[10, 11] 
Specifically, NSAIDs result in opening of the mitochondrial permeability transition pore 
with secondary decrease in transmembrane potential, loss of oxidative phosphorylation, 
release of cytochrome C and calcium into the cytosol, and finally apoptosis.[8] The role 
of mitochondrial dysfunction in NSAID enteropathy is further supported by the finding 
that inhibition of c-jun-N-terminal kinase, a regulator of mitochondria-induced 
apoptosis, reduces the severity of NSAID enteropathy.[12] The exact mechanism by 
which NSAIDs induce mitochondrial damage is unclear, although mitochondrial 
production of reactive oxygen species (ROS) has been implicated.[10] Moreover, ROS 
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produced by the mitochondria have been shown to alter the expression of zonula 
occludens-1 (ZO-1), a protein important for intracellular tight cell junctions, resulting in 
increased mucosal permeability.[13] Mucosal permeability is further affected by  
decrease in ATP levels following mitochondrial damage.[14]  
The topical effects of NSAIDs are related to the parent drug but can also be 
exacerbated by the presence of oxidative metabolites that arise from cytochrome P450 
(CYP)-mediated metabolism of the parent drug. IECs within the small intestine have 
multiple CYP forms that generate oxidative metabolites of the parent drug that may 
further exacerbate the topical effects of NSAIDs.[15] Clearly the topical effects of 
NSAIDs on intestinal mucosa are an important component of NSAID enteropathy. 
Inhibition of Cyclooxygenase 
The well-described mechanism by which NSAID exert their anti-inflammatory 
effects is COX inhibition, encoded by prostaglandin endoperoxide synthase (PTGS).[16] 
COX is responsible for the breakdown of arachidonic acid into various prostanoids. Two 
isoforms of COX have been described: COX-1 and COX-2. It is generally accepted that 
COX-1 is the constitutively expressed form and is responsible for production of the 
beneficial prostaglandins that serve to maintain mucosal blood flow and mucus 
production, whereas COX-2 is the inducible isoform responsible for production of 
inflammatory prostaglandins.[17] This paradigm is the rationale for tremendous research 
and development efforts for developing COX-2-selective NSAIDs that would maintain 
the beneficial prostaglandins by preserving COX-1 but reduce inflammatory 
prostaglandins by inhibition of COX-2. Interestingly, COX-1 knock-out mice (PTGS-1-
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/-) do not develop enteropathy and COX-2 knockout mice (PTGS-2-/-) do not develop 
the same enteropathy as seen with NSAID administration.[18, 19] Others have 
demonstrated repeatedly that some degree of concomitant inhibition of COX-1 and 
COX-2 is necessary to induce enteropathy and inhibition of one isoform results in 
upregulation of the other.[20]  It has been suggested that COX-2 inhibition is more 
important than COX-1 inhibition in inducing NSAID enteropathy.[21] The importance 
of COX-2 in mucosal protection also has been shown by epidemiological studies 
demonstrating reduced NSAID gastropathy but no reduction, and perhaps even an 
increase, in the incidence of NSAID enteropathy in people despite the introduction of 
COX-2-selective NSAIDs to the market.[22] Taken together, these findings suggest that 
COX-2 does, in fact, provide mucosal protection and that while COX-inhibition can 
delay healing or increase the severity of NSAID enteropathy, COX-inhibition alone is 
not responsible for NSAID enteropathy. 
Innate Inflammatory Response 
Subsequent to the topical effects of NSAIDs on IECs, release of ROS, ROS-
modified ZO-1 proteins, and loss of barrier function, there is an invasion of luminal 
contents into the bowel wall. This, in turn, activates the innate inflammatory response. 
The finding that Rag2-/- mice and athymic mice develop similar degrees of 
indomethacin-induced injury as do mice with competent adaptive immune responses 
indicates that NSAID enteropathy is primarily driven by innate rather than adaptive 
immune responses.[23, 24] In particular, Toll-like receptor 4 (TLR4) signaling activated 
by bacterial LPS plays a critical role in the pathogenesis of NSAID enteropathy.  Mice 
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that lack TLR4 develop less severe lesions than isogeneic TLR4-competent strains.[25] 
Additionally, TLR4 deficiency also inhibited NSAID-induced upregulation of pro-
inflammatory cytokines with concomitant decrease in disease severity.[26] TLR4 
appears to be an important player in mucosal barrier function and inflammation.[27] 
Stimulation of TLR4 by ligands activates MyD-88 which, in turn, incites production of 
pro-inflammatory cytokines such as interleukin (IL)-1β and tumor necrosis factor alpha 
(TNF-α) which contribute to severity of disease.[28-30] These, in turn, recruit more 
inflammatory cells to the area, primarily neutrophils.  
Neutrophilic inflammation is the hallmark of NSAID enteropathy and neutrophils 
are the key effector cells of this disease.[31-33] Neutrophils are recruited to the area 
following loss of barrier function and incite further inflammation by release of pro-
inflammatory mediators including IL-1β and TNF-α. Highlighting the importance of this 
pathway is the fact that TNF-α knockout mice develop less severe enteropathy than 
wild-type mice, and treatment with anti-TNF-α pharmaceuticals lessens the severity of 
disease.[29, 30, 34] An additional mechanism by which neutrophils contribute to the 
inflammation in NSAID enteropathy is by further oxidation of parent NSAIDs (or their 
metabolites) to a more active form through the activity of myeloperoxidase.[35] It 
appears that the neutrophil response is not responsible for the initial break in barrier 
function but rather plays a critical role in progression of the injury.  
Although the steps described in this multi-hit theory of NSAID enteropathy are 
clearly important and valid, some aspects of the pathogenesis of NSAID enteropathy are 
not adequately explained by this process. For example, it remains unclear why some 
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individuals are more sensitive to the effects of NSAIDs than others, why the most 
severely affected region of the GI tract is the distal small intestine, and how probiotics or 
diet influence the severity of disease. Some of these questions can be explained by 
interactions between the gut microbiota and NSAIDs.  The remainder of this review will 
address the complex interactions between NSAIDs and the microbiota, and how the 
microbiota influences diseases severity.   
Effects of NSAIDs on the Microbiota 
We first consider the effects of NSAIDs on the intestinal microbiota. It is well-
established that NSAID administration causes a dysbiosis that contributes to 
development of disease.[36-38] This dysbiosis is characterized by an increase in gram 
negative bacteria and this shift in composition of the microbiota is consistently observed 
both in animal models and in people using NSAIDs clinically.[32, 39-42] In concert with 
an increase in gram negative bacteria, there appears to be a loss of specific gram positive 
bacteria including Bifidobacteriaceae, Lachnospiracea, and Lactobacillacea.[39, 43, 44] 
Administration of probiotics containing these families of microbes ameliorates NSAID 
enteropathy, further suggesting this particular shift in the microbiota composition is 
important to the development of NSAID enteropathy.[44-47] Moreover, co-
administration of proton pump inhibitors (PPI), which induce an enteropathy 
characterized by loss of similar types of microbes as NSAIDs, worsens NSAID-
enteropathy.[48, 49]  
The mechanism by which NSAIDs cause dysbiosis is unknown. One possibility 
is that ROS released from IECs following NSAID-induced mitochondrial damage 
 8 
 
contributes to this dysbiosis, because ROS molecules released during intestinal 
inflammation can induce a dysbiosis.[50] When ROS molecules react with luminal 
substrates such as thiosulphates, they subsequently act as electron receptors for 
pathogens that use respiration which allows the respiring bacteria to outcompete 
commensal bacteria that use fermentation for generating energy.[51] Although this 
mechanism of dysbiosis has not been demonstrated for NSAID enteropathy as it has for 
other models of mucosal inflammation that generate ROS, ROS are released by IECs 
secondary to topical effects of NSAIDs.[10, 11, 52] It is unclear for NSAID enteropathy 
to what degree these ROS molecules from IECs enter the lumen of the GI tract and 
interact with the microbiota.  Another mechanism by which NSAIDs might induce a 
dysbiosis is the antimicrobial properties of some NSAIDs.[53-55] Irrespective of the 
mechanism, the dysbiosis associated with NSAIDs appears to greatly influence all other 
aspects of the pathophysiology of NSAID enteropathy.  
Effects of the Microbiota on NSAIDs and NSAID Enteropathy 
The microbiota is critically important to host health.  This is certainly true for GI 
diseases where alterations of the intestinal microbiota, and host response to the 
microbiota, have been linked to numerous diseases including peptic ulcers, inflammatory 
bowel disease (IBD), ulcerative colitis (UC), colorectal cancer (CRC), and many others. 
This interaction appears to play a crucial role in NSAID enteropathy.   Pretreatment with 
antibiotics that primarily target gram-negative bacteria greatly ameliorates NSAID 
enteropathy.[39, 56] Moreover, germ-free animals do not develop enteropathy in 
response to NSAIDs.[39, 57] While these findings demonstrate an association between 
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the microbiota and NSAID-induced enteropathy, they do not address the mechanistic 
basis of this relationship.  Thus, we next consider mechanisms by which the microbiota 
can impact the development of NSAID enteropathy.  
The Microbiota Influences the Topical Effects of NSAIDs 
The microbiota has been shown to enhance the topical effects of NSAIDs by 
bacterial β-glucuronidation. Many bacteria, including some found in the gastrointestinal 
tract, possess β-glucuronidase enzymatic activity. When NSAIDs are administered 
(orally or parenterally) they undergo enterohepatic circulation. In the liver, NSAIDs are 
conjugated via glucuronidation and released into the biliary tree.[58-60] Bacterial β-
glucuronidases remove the glucuronide group, releasing either the parent drug or the 
oxidized metabolite such that NSAIDs are able to damage IEC membranes and then re-
enter these cells.  Pharmacologic inhibition of bacterial β-glucuronidases attenuates the 
severity of NSAID enteropathy indicating that bacterial β-glucuronidation contributes to 
development of NSAID enteropathy.[6, 61] Interestingly, the distal small intestine 
contains higher β-glucuronidase activity than the remainder of the GI tract.[62] This 
might explain in part the finding that the most severe NSAID-induced intestinal injury 
occurs in the distal small intestine despite the fact that higher concentrations of NSAIDs 
are likely to be found more proximally in the small intestine following their release in 
the bile. 
In a related manner, the dysbiosis caused by NSAIDs may contribute to the 
severity of NSAID enteropathy by the action of the microbiota on bile acids. Primary 
bile acids are made in the hepatocyte, and are secreted in the proximal small intestine 
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where they come into contact with the gut microbiota.[63] Some bacteria in the gut are 
capable of acting on hydroxyl groups of primary bile acids to form secondary bile acids 
(SBAs).[64] The SBAs can have adverse effects. For example, SBAs (e.g., deoxycholic 
acid and lithocholic acid) have been shown to result in increased paracellular 
permeability in the gut and to damage the cell membrane of IECs, thus enhancing the 
topical effects of NSAIDs which leads to further mucosal damage and loss of barrier 
function.[65, 66] The SBAs function in digestion of nutrients and are critical for 
enterohepatic circulation. Fecal and even circulating levels of SBAs have been 
associated with a number of different alimentary diseases including CRC, liver cancer, 
and IBD. Dysbiotic states can alter the capacity of the microbiota to modify bile acids by 
increasing or decreasing the types of bacteria that act on primary bile acids and this may 
be the case with NSAID-induced dysbiosis.[67, 68] It is important to note that the 
balance of bile acids is important: decreased bile acid concentrations in the GI tract lead 
to bacterial overgrowth of some types of bacteria whereas increased bile acid 
concentrations can result in inflammation and disease.[69]  
Interestingly, bile acids, and specifically SBAs, have been linked to NSAID 
enteropathy. A number of studies have suggested bile acids increase NSAID-induced 
cytotoxicity, thereby enhancing the topical effects of NSAIDs on the mucosa.[70, 71] In 
addition, bile duct ligation in rodent models of NSAID-enteropathy prevents NSAID 
induced intestinal injury, thus highlighting the importance of bile and enterohepatic 
circulation in this phenotype.[72] Taken together these findings suggest that dysbiosis 
resulting in an altered bile acid profile in the GI tract that enhances the topical effects of 
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NSAIDs might be another mechanism by which the microbiota influences the topical 
effects of NSAIDs and thus overall disease severity in NSAID enteropathy.  
The Microbiota Influences the Host Innate Immune Response 
Microbes have highly conserved molecular signatures, referred to as pathogen 
associated molecular patterns (PAMPs), that are recognized by the host via germ-line-
encoded receptors, referred to as pattern recognition receptors (PRRs) including the 
TLRs. The interaction of PAMPs and PRRs is central to the innate immune response of 
the host and has been well-reviewed.[73] In the GI tract, the interaction of PAMPs with 
TLR4 has been shown to be critically important for maintenance of GI mucosal 
homeostasis as well as for mediating inflammation that may lead to diseases such as 
IBD, CRC, and NSAID enteropathy.[32, 74-76] Bacterial recognition by TLR receptors 
have been shown to modulate intestinal function; therefore, perturbations of the 
microbiota (i.e., NSAID-induced dysbiosis) can alter these pathways and result in 
increased intestinal dysfunction and damage.[77] For example, NSAIDs are known to 
increase gram negative bacteria.  Because LPS is a component of the cell wall of gram 
negative bacteria, it is logical that increased gram negative bacteria will result in 
increased LPS, the canonical ligand of TLR4 resulting in increased TLR4 signaling.[32, 
39-41]   Increased amounts of LPS invading the deeper layers of the intestinal wall 
following NSAID-induced loss of barrier function could bind to TLR4 and result in 
downstream signal transduction. Indeed, LPS, TLR4, and its downstream pathways 
including MyD-88 have been shown to be critical players in the pathophysiology of 
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NSAID enteropathy and expression of TLR4 appears to be upregulated during NSAID-
induced inflammation (similar to what is found in people with IBD).[25, 32, 78] 
Another mechanism by which NSAID-induced dysbiosis might influence TLR 
signaling is by altering the expression and/or spatial location of TLRs on IECs. 
Enteropathy associated with NSAIDs (and other GI inflammatory diseases) results in 
increased expression by IECs of some TLRs, particularly TLR4.[32, 40, 79]  The IECs 
are polarized and as such TLR molecules can be located on the apical side and the 
basolateral surface. Apical molecules are located on the luminal side of the IEC and 
therefore are likely to come into contact with PAMPs associated with the gut 
microbiome. In contrast, basolaterally-located molecules only come into contact with 
PAMPs that have traversed the mucosal barrier (i.e., following intestinal injury). 
Differences in spatial arrangement of TLRs have been shown to be important in some 
inflammatory disorders of the GI tract such as IBD. A hallmark of Crohn’s disease is 
lack of tolerance to the microbiota.[80] Interestingly, people with active Crohn’s disease 
express TLR4 on the apical portion of colonic IECs at a much higher concentration than 
unaffected people, implicating alteration in spatial location of TLR4 in development of 
inflammatory disorders of the GI tract.[79]  The gut microbiota can influence the spatial 
orientation of TLRs on IECs by increasing apical expression.[81] It is thus plausible that 
the composition of the microbiota not only alters expression of TLRs but also the  
location/distribution of the TLRs on IECs.  It remains to be determined whether the 
spatial orientation of TLRs and other PRRs are altered by NSAID administration or 
during NSAID enteropathy, and whether this spatial alteration is microbiota-dependent. 
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Dysbiosis Alters Microbiota-Derived Metabolite Profile with 
Multiple Implications for NSAID Enteropathy 
Dysbiosis results in intestinal inflammation and loss of barrier function.[82] The 
mechanism by which dysbiosis induces inflammation, however, remains unclear. One 
possible explanation is the loss of commensal bacteria during dysbiosis. Some 
commensals produce metabolites that are beneficial for host IECs and maintenance of 
intestinal barrier function.  For example, people with Crohn’s disease have a dysbiosis 
that is characterized by a loss of the critically important commensal bacteria 
Fecalibacterium and Roseburi which produce large quantities of short-chain fatty acids 
(SCFAs).[83-85] The SCFAs generated by intestinal commensal bacteria exert several 
beneficial effects on the host including maintaining gut homeostasis and reducing 
inflammation; therefore, any dysbiosis that results in loss of SCFAs might contribute to 
inflammation.[48, 86, 87] Several reports document that NSAIDs reduce the number of 
intestinal bacteria of the phylum Firmicutes and, less frequently, Bacteroidetes, both of 
which produce SCFAs.[32, 36, 42, 78] Interestingly, some reports have indicated that 
culture supernatant alone (i.e., no platonic bacteria) can successfully prevent NSAID 
enteropathy.[48, 86] These findings further indicate that microbiota-derived metabolites 
are critically important in affording protection from NSAID-induced intestinal injury 
and that dysbiosis, resulting in loss of these metabolites, contributes to disease severity. 
In addition to SCFAs, the microbiota produces many other metabolites thought to 
be largely responsible for microbiota-host interactions.[88] The metabolome of the 
microbiota has been shown to be altered in dysbiotic states. It is reasonable, therefore, to 
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assume that NSAID-induced dysbiosis alters the intestinal metabolome which in turn 
might contribute to intestinal injury by altering inter-kingdom signaling.[89, 90] For 
example, several microbiota-derived tryptophan metabolites are involved in inter-
kingdom signaling between the host and the intestinal microbiota.[91] Moreover, many 
tryptophan metabolites exert anti-inflammatory activities on the host via a variety of 
mechanisms, many of which have yet to be identified.[92, 93] Recently, we reported that 
co-administration of indole, a tryptophan microbiota-derived metabolite, attenuated 
severity of NSAID enteropathy in a murine model.[32] Currently, it is unknown to what 
degree NSAID-induced dysbiosis alters the metabolome and to what extent this altered 
microbiota function contributes to disease severity. The fact, however, that co-
administration of this microbiota-derived metabolite decreased disease severity gives 
further support to the idea that the mechanism by which the microbiota might alter 
disease severity is via the presence or absence of metabolites that regulate host immune 
response and that help maintain mucosal homeostasis.  
Conclusion  
The pathophysiology of NSAID enteropathy is complex and much work remains 
to determine the exact mechanisms by which it develops. All NSAIDs inhibit COX 
activity in a microbiota-independent manner.  While this inhibition may be a factor in 
disease severity or recovery form NSAID-induced damage, COX inhibition alone does 
not fully explain the pathophysiology of NSAID enteropathy.  It is increasingly evident 
that the microbiota influences many aspects of this prevalent condition. Use of NSAIDs 
can also induce a dysbiosis due to the antimicrobial effects of NSAIDs, a shift in 
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metabolites produced by the microbiota resulting from NSAID-induced inflammation, or 
both factors (possible acting synergistically).  This NSAID-associated dysbiosis 
subsequently greatly impacts other determinants of the pathogenesis of NSAID 
enteropathy. Undoubtedly, NSAIDs have a topical effect whereby their presence at the 
mucosal surface induces epithelial cell damage and eventually cell death via alterations 
of cell membranes, mitochondrial injury, and ROS production. Although this aspect of 
the pathophysiology exists independent of the microbiota, it can be modulated by the 
microbiota due to β-glucuronidase activity of microbiota as well as production of SBAs 
that render IECs more permeable to NSAIDs and increase enterophepatic circulation of 
NSAIDs. Following topical injury, barrier function becomes compromised and bacteria 
and other luminal contents invade the mucosa and induce an innate immune response. 
The innate immune response can be greatly influenced by the microbiota, either 
worsened by factors such as the relative amounts of pro-inflammatory mediators like 
LPS, or ameliorated by the presence of anti-inflammatory microbiota-derived 
metabolites such as SCFAs or indole. Finally, host-microbiota interaction is mediated by 
PRRs and PAMPs, and dysbiosis can alter both the expression and location of host-
derived PRRs as well as relative abundance of PAMPs further contributing to NSAID 
enteropathy. Taken together these findings suggest an important role for the microbiota 
in the pathophysiology of NSAID-induced intestinal injury.  Further elucidation of the 
role of the microbiota and its metabolites in NSAID enteropathy will likely contribute 
novel approaches to control this highly prevalent if under-recognized health problem that 
is of global concern. The therapeutic value, relatively low cost, and widespread 
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availability of NSAIDs indicate that these drugs will continue to be used despite their 
adverse effects. Thus, there is great need for the identification of novel diagnostic 
methods for earlier identification of the condition and for therapeutic or prophylactic 
medications that can be co-administered with NSAIDs to reduce the impact of NSAID 
enteropathy.  Further elucidation of the role of the microbiota and its metabolites in 
NSAID enteropathy will likely contribute novel approaches to control this highly 
prevalent if under-recognized problem that is a global health concern. 
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CHAPTER II 
THE MICROBIOTA-DERIVED METABOLITE INDOLE DECREASES MUCOSAL 
INFLAMMATION AND INJURY IN A MURINE MODEL OF NSAID 
ENTEROPATHY 
 
Introduction 
 Non-steroidal anti-inflammatory drugs (NSAIDs) are among the most frequently 
used medications worldwide for routine relief of pain or fever, to manage various forms 
of arthritis and inflammatory intestinal disorders, and to prevent or treat alimentary 
cancers.[94, 95] Despite their effectiveness for managing these varied and highly 
prevalent conditions, NSAIDs cause damage to the gastrointestinal (GI) tract.  Although 
methods for diagnosis and effective treatment of NSAID-induced lesions of the proximal 
GI tract (i.e., gastropathy) have been well documented, the pathogenesis, diagnosis, and 
treatment of NSAID-induced damage of the GI tract distal to the duodenum (known as 
NSAID enteropathy, primarily affecting the distal jejunum and ileum) remain 
unclear.[96, 97] The magnitude of the problem of NSAID enteropathy is alarmingly 
high.  In the United States, NSAID enteropathy results in approximately 100,000 
hospitalizations and 16,500 deaths each year.[98] Additionally, 2-thirds of both short- 
and long-term NSAID users develop distal small intestinal lesions.[2, 99] Although the 
                                                 
* The Microbiota-derived Metabolite Indole Decreases Mucosal Inflammation and Injury 
in a Murine Model of NSAID Enteropathy, Canaan M. Whitfield-Cargile, Noah D. 
Cohen, Robert S. Chapkin et al (2016), Gut Microbes, 7 (3): 246-261, reprinted by 
permission of Taylor & Francis LLC, (http://tandfonline.com). 
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use of either NSAIDs considered to be safer for the GI tract or other ancillary therapies 
have reduced the incidence and severity of NSAID-induced gastropathy, the incidence of 
NSAID enteropathy has remained constant or has increased.[22]    
The pathophysiology of NSAID enteropathy is complex and incompletely 
understood.[100] It appears to involve deleterious effects of NSAIDs on the intestinal 
mucosa including enterocyte cell death, increased mucosal permeability, and interaction 
of the damaged mucosa with luminal contents including bacteria (GI microbiota) and 
bacterial products or components such as lipopolysaccharide (LPS).[10, 97]  The GI 
microbiota has been implicated as an important contributor to NSAID enteropathy.[23, 
39, 42, 49, 78] Administration of NSAIDs causes a dysbiosis characterized by a 
reduction of the predominately gram-positive phylum Firmicutes and a corresponding 
increase of gram-negative bacteria.[42, 78] Germ-free rats lacking intestinal microbiota 
do not develop NSAID enteropathy, whereas they develop NSAID-induced intestinal 
lesions when colonized with gram-negative bacteria.[39] Concurrent administration of 
NSAIDs and antimicrobials targeting gram-negative bacteria reduces the severity of 
NSAID-induced gastrointestinal lesions in rats.[23] 
A mechanism by which the microbiota might influence NSAID-induced 
intestinal mucosal damage is by producing metabolites that protect intestinal epithelial 
cells.[92, 101] Previously, we identified tryptophan metabolites, including indole, as an 
important class of GI microbiota-derived compounds.[91]  Indole is a quorum-sensing 
molecule produced by bacterial metabolism of L-tryptophan that mediates 
communication among bacterial population and inter-kingdom signaling between the 
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host and microbe.[92, 102, 103]  Indole improves barrier function and decreases 
intestinal inflammation in vitro and in vivo.[92, 101] Moreover, several other tryptophan 
metabolites reportedly exert similar salutary effects on the intestinal epithelium.[93, 104] 
Therefore, we hypothesized that indole would mitigate the severity of NSAID 
enteropathy.  To investigate this hypothesis, we co-administered indole with the NSAID 
indomethacin and demonstrated a reduction in severity of mucosal injury caused by 
indomethacin alone.  To determine whether the protective effects of indole were 
associated with alterations in the GI microbiota, we characterized the effects of 
administration of NSAIDs, indole, and their co-administration on the composition and 
diversity of the fecal microbiota.  We observed that the co-administration of indole with 
indomethacin resulted in maintenance of or even an increase of an important member of 
the Firmicutes phylum.  Finally, to better understand the mechanisms of NSAID 
enteropathy and the effects of indole on these processes, we performed RNA-Seq of the 
distal small intestinal epithelium in mice that were untreated or treated with 
indomethacin, indole alone, or the combination of indomethacin and indole.  Pro-
inflammatory pathways associated with innate immune responses were up-regulated by 
indomethacin administration relative to control mice, and co-administration of indole 
significantly mitigated the up-regulation of these pathways concomitant with reduced GI 
pathology. 
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Materials and Methods 
Animal protocols were approved by the Texas A&M Institutional Animal Care 
and Use Committee in accordance with appropriate institutional and regulatory bodies’ 
guidelines.  
Mice and Treatments 
Eight- to 10-week-old specific-pathogen-free C57BL/6J mice were purchased 
and allowed to acclimate for 2 weeks. Mice were fed standardized laboratory rodent diet 
and sterile water ad libitum. Mice were randomly divided into the following 4 groups 
(n=5 mice/group): 1) NSAID (indomethacin); 2) indole; 3) NSAID + indole; and, 4) 
untreated controls.  Mice were then rehoused on the basis of treatment group assignment, 
with 5 animals/group-cage. To induce NSAID enteropathy, mice in group 1 were 
gavaged once daily with indomethacin (5 mg/kg; for 7 days; Sigma Aldrich, St. Louis, 
MO) dissolved in DMSO (Sigma Aldrich, St. Louis, MO) and further diluted in 
phosphate buffered saline (PBS). Mice in group 2 received indole by gavage (20 mg/kg; 
once daily for 7 days; Sigma Aldrich, St. Louis, MO) dissolved in sterile water warmed 
to 55°C. Mice in group 3 received indole co-administered with indomethacin by gavage 
at the dosages described above.  All mice were gavaged with equal volumes (200 μL) 
and equal concentrations of DMSO (0.001%).   
Sample Collection 
Feces were collected daily by placing individual animals in sterile plastic cups 
that were RNase- and DNase-free until they passed feces. The mice were immediately 
returned to their home cages and the feces immediately flash frozen at -80°C. All 
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animals were euthanized via CO2 asphyxiation on day 8 (i.e., after 7 days of treatment). 
The small intestine was harvested, opened longitudinally, rinsed with ice-cold PBS, and 
the distal 1/3 of the intestinal mucosa was scraped for tissue gene expression analysis. 
The remaining small intestine was fixed in 4% paraformaldehyde, Swiss-rolled, paraffin-
embedded, and stained with hematoxylin and eosin.  The spleen and mesenteric lymph 
nodes (MLN) were harvested, and immediately placed in ice cold RPMI-1640-c + 10% 
fetal calf serum (FCS: Life Technologies, Carlsbad, CA), homogenized, and prepared as 
a single cell suspension for flow cytometric analysis as previously described.[105] 
Fecal Calprotectin ELISA 
A murine calprotectin ELISA kit (HK214, Hycult Biotech, Plymouth Meeting, 
PA) was used according to the manufacturer’s protocol with slight modifications. 
Briefly, 100 mg of feces was homogenized in extraction buffer (0.1 M Tris, 0.15 M 
NaCl, 1.0 M urea, 10 mM CaCl2, 0.1 M citric acid monohydrate, 5 g/l bovine serum 
albumin (BSA) and 0.25 mM thimerosal [pH 8.0]). The homogenate was centrifuged at 
10,000 x g at 4°C for 20 minutes and the supernatant used as directed in manufacturer’s 
protocol. 
Tissue RNA Extraction, Sequencing, and Processing 
RNA was extracted from the mucosal scrapings using an RNeasy mini kit 
(QIAGEN, Redwood City, CA) following the manufacturer’s instructions and including 
on-column DNase treatment.  RNA quantity was determined using a Nanodrop 
spectrophotometer (Fisher Thermoscientific) and the quality was assessed using the 
Nano6000 chip on a Bioanalyzer 2100(Agilent Technologies). Only RNA with an 
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integrity number (RIN) > 8 was used. The samples were randomized before beginning 
the RNA-Seq library preparation.  Sequencing libraries were made using 250 ng of RNA 
and the TruSeq RNA Sample Preparation kit (Illumina) following the manufacturer’s 
instructions.  A volume of 2.5 µl of ERCC spike-in RNA control mix (Life 
Technologies) was added to the starting RNA at a dilution of 1:1000.  The libraries were 
pooled and sequenced on an Illumina HiSeq 2500 at the Texas AgriLife Genomics and 
Bioinformatics Services Core Facility (College Station, TX).  Sequencing data were 
provided in a de-multiplexed format and aligned using Spliced Transcripts Alignment to 
a Reference (STAR) software with default parameters and referenced against the 
genome of Mus musculus (Ensembl version GRCm38).[106] Differentially expressed 
genes were determined using EdgeR based on the matrix of gene counts.[107]53 Gene 
lists were analyzed through use of QIAGEN’s Ingenuity ® Pathway Analysis (IPA, 
QIAGEN, Redwood City, CA http://www.qiagen.com/ingenuity). Sequence data were 
uploaded into NCBI small reads archive (Accession number PRJNA290483). 
Microbiota DNA Extraction, Sequencing, and Processing 
Microbiota 16S rRNA gene sequencing methods were adapted from the methods 
developed for the NIH-Human Microbiome Project.[108, 109] Briefly, bacterial 
genomic DNA was extracted using MO BIO PowerSoil DNA Isolation Kit (MO BIO 
Laboratories) according to the manufacturer’s protocol. The 16S rDNA V4 region was 
amplified by PCR and sequenced in the MiSeq platform (Illumina) using the 2 x 250-bp 
paired-end protocol yielding paired-end reads that overlap almost completely.[110] The 
primers used for amplification contain adapters for MiSeq sequencing and dual-index 
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barcodes so that the PCR products can be pooled and sequenced directly. The software 
suite Quantitative Insights Into Microbial Ecology (QIIME v1.9 [http:// 
qiime.sourceforge.net]) was used for data processing and analysis.[111] The raw 
sequence data were de-multiplexed, and low-quality reads were filtered using the 
database’s default parameters. Chimeric sequences were detected using Uchime and 
removed prior to further analysis.[112] Sequences were then assigned to operational 
taxonomic units (OTUs) using an open-reference OTU picking protocol 
[http://qiime.org/scripts/pick_open_reference_otus.html] with UCLUST software in 
QIIME based on 97% identity with the Greengenes database (v13_5).[113-115] To 
adjust for uneven sequencing depth among the samples, each sample was rarefied to an 
even sequencing depth (10,512 reads/sample) prior to further analysis.  
Alpha rarefaction, beta diversity measures, richness, taxonomic summaries, and 
tests for significance were calculated and plotted using QIIME. The weighted and 
unweighted Unifrac distances were calculated for comparison of beta diversity. 
Differences in microbial communities among the treatment groups were investigated by 
visual assessment of clustering on principal component analysis (PCA) and by analysis 
of similarity (ANOSIM) calculated on unweighted UniFrac distance metrics.[116-118] 
ANOSIM is a non-parametric test of difference between 2 or more groups based on a 
distance metric. This test gives an R value between -1 and 1 where large positive R 
values indicate a large magnitude of dissimilarity between the groups and small R values 
indicate small magnitudes of dissimilarity; the P value provides statistical significance.  
When ANOSIM identified significant differences among groups, then pairwise 
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ANOSIM was performed to determine which groups differed significantly and similarity 
percentage (SIMPER) was used to examine which features contributed to the differences 
among groups. ANOSIM, SIMPER, and PCA plots were performed with PAST 
v3.05.[119] 
The software Phylogenetic Investigation of Communities by Reconstruction of 
Unobserved States (PICRUSt) was used to predict the metagenome.[120] Sequencing 
data were prepared as described above, but sequences were then clustered into OTUs 
using a closed-reference OTU picking protocol at the 97% sequencing identity level 
[http://qiime.org/scripts/pick_closed_reference_otus.html]. The resulting OTU table was 
normalized by the expected copy number(s) of the 16s rRNA gene in each OTU. 
PICRUSt was then used to predict the metagenome 
[https://picrust.github.io/picrust/tutorials/metagenome_prediction.html#metagenome-
prediction-tutorial]. Each sample was rarefied to an even sequencing depth to adjust for 
uneven sequencing depth prior to further analysis. Differences in the metagenomes 
among the groups were investigated by visual assessment of clustering on PCA and by 
analysis of similarity (ANOSIM) calculated on Bray Curtis dissimilarity metric.  
Metabolite Extraction from Fecal Samples 
Metabolites from the fecal contents were extracted using a solvent-based method 
as previously described.[91] Briefly, fecal pellets were homogenized using a 
homogenizer (Omni International) with equal volume of cold methanol and half volume 
of chloroform. The samples were then centrifuged at 10,000 g at 4°C (Thermo Fisher 
Scientific) for 10 min. Supernatant was passed through a 70-µm sterile nylon cell 
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strainer (Falcon) and 0.6 ml of ice cold water was added. The samples were vortex and 
centrifuged again at 10,000 g for 5 minutes. The upper phase and lower phase were 
collected and 400 µl of upper phase was dried to a pellet using a vacufuge (Eppendorf, 
Hauppauge, NY), and then reconstituted in 50 μl of  methanol/water (1:1, v/v). The 
samples were stored at −80°C until analysis. Tryptophan metabolites in the samples 
were detected and quantified on a triple quadrupole linear ion trap mass spectrometer 
(3200 QTRAP, AB SCIEX, Foster City, CA) coupled to a binary pump HPLC 
(Prominence LC-20, Shimazu, Concord, Ontario, Canada). 
Flow Cytometry 
Spleens and MLNs were processed individually to single-cell suspensions with 
frosted glass slides in RPMI-c + 10% FCS, and spleen cells underwent red blood cell 
lysis.[121] Cell suspensions were plated in individual wells, washed with 0.5% BSA in 
PBS, surface-stained for CD11b-AlexaFluor488 (eBioscience cat. #53-0112-82) and Gr-
1-biotin (BD cat. #553125), followed by streptavidin-PE (eBioscience cat. #12-4317), 
fixed with 0.4% paraformaldehyde, and samples were acquired on a BD FACS Aria II in 
the College of Medicine Cell Analysis Facility (COM-CAF) at the Texas A&M Health 
Science Center. 
Histology and Small Intestinal Morphometric Measurements 
The stained sections of the small intestine were analyzed by a board-certified 
veterinary pathologist (BRW) blinded to treatment group. The slides were scored as 
previously described for intestinal inflammation.[122] Briefly, mucosal injury was 
determined by the following parameters scored from 0 (no evidence) to 3 (marked): 
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mucosal ulceration, mucosal erosion, and presence of squamified epithelium. 
Inflammatory changes were scored similarly based on the following parameters: 
lymphocytic infiltration, plasma cell infiltration, and neutrophilic infiltration. Finally, an 
overall evidence of injury score was used to document total injury graded from 0 (none) 
to 4 (marked).  Morphological parameters were obtained from digitally scanned slides 
using SPOT vr 5.0 software. Three sets of measurements from 3 separate sections were 
recorded for each animal by an observer blinded to treatment group. Measurements 
consisted of villus height, crypt depth, and submucosal mural thickness. The ratio of the 
villus height to crypt depth was calculated (Figure A-1.1). 
Data Analysis 
Results were expressed as mean ± 95% confidence interval unless indicated 
otherwise. For all analyses, significance was set P ≤ 0.05. Data were analyzed using S-
PLUS statistical software (Version 8.2, TIBCO Inc., Seattle, WA) unless otherwise 
noted.  Histology scores, the proportion of neutrophils in the spleen and MLNs, ratios of 
villus height to crypt depth, submucosal thicknesses, paired differences between Day 7 
and Day 0 in phyla and families, and fecal tryptophan metabolites were compared 
among treatment groups using a generalized linear model with post hoc testing for 
pairwise differences among groups using the method of Sidak.[123]  To meet statistical 
assumptions underlying the generalized linear model, the histology scores were 
converted to ranks and the neutrophil data were log10 transformed prior to analysis.  
Ratios of villus height to crypt depth and submucosal thicknesses were compared among 
groups using a generalized linear model with post hoc testing for pairwise differences 
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among groups using the method of Sidak. Fecal calprotectin concentrations were 
analyzed as a function of treatment group, time (Day 0 [baseline] and Day 7), and their 
interaction using linear mixed-effects modeling with treatment group and time modeled 
as fixed, categorical effects and individual mouse modeled as a random effect to account 
for repeated measures on individual mice.  Paired differences between Day 0 and Day 7 
in phyla and families were compared among groups using a generalized linear model and 
post hoc testing for pairwise differences among groups using the method of Sidak. 
Results 
Indole Reduced the Severity of NSAID Enteropathy 
Calprotectin ELISA of fecal samples collected on days 0 and 6 revealed that co-
administration of indole with indomethacin significantly decreased fecal calprotectin 
levels (Figure 1A).  Moreover, attenuation of NSAID-induced small intestinal damage 
was confirmed by microscopic pathology scores (Figure 1B and C) of mice in which 
indole was co-administered with indomethacin. The reduction in mean microscopic 
pathology scores were corroborated by morphological parameters which revealed 
maintenance of villus height:crypt depth ratio (Figure 1D) and thickness of the 
submucosal layers (Figure A-1.1) in mice in which indole was co-administered. 
Indomethacin had a negligible effect on the large intestine (data not shown), consistent 
with evidence that indomethacin induces small intestinal ulcerations in mice in a 
location similar to where NSAIDs injure people.[29, 124-127] 
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Indole reduced indomethacin-induced neutrophilic infiltration of spleen and MLN  
Neutrophilic inflammation is primarily responsible for NSAID enteropathy, 
therefore, we quantified the abundance of neutrophils in the spleen and MLNs as 
measures of systemic neutrophilic response and trafficking of neutrophils though the GI 
tract, respectively.[31, 33] Indomethacin treatment resulted in a significant increase in 
neutrophils (defined as both CD11b- and GR-1 double-positive; Figure A-1.2) in both 
the spleen (Figure 1E) and MLNs (Figure 1F), and co-administration of indole 
significantly decreased neutrophilic infiltration of these tissues.[128] Taken together, 
these data demonstrate that indomethacin induced small intestinal injury in mice that 
was accompanied by neutrophilic infiltration of the spleen and mesenteric lymph node 
and that co-administration of indole attenuated the small intestinal injury and limited 
neutrophilic infiltration of the spleen and MLN caused by indomethacin. 
 
 
 
Pairwise ANOSIM R-
values         
  Control NSAID Indole NSAID+Indole 
Control   0.5487* 0.2 0.2813 
NSAID 0.5487*   0.2615 0.4444 
Indole 0.2 0.2615   0.1938 
NSAID+Indole 0.2813 0.4444 0.1938   
Table 1 Pairwise ANOSIM reveals differences between NSAID-treated and control 
mice.  
Pairwise ANOSIM R-values based on the unweighted Unifrac distance metric at day 7. 
Only the difference between control and NSAIDs was significantly different than 0. * R 
values is significantly (P < 0.05) different than a value of 0. 
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A) Fecal calprotectin levels were determined by ELISA on fecal samples on Day 0 and 
then again after 6 days of therapy with indomethacin, indole, or the combination. B) 
Microscopic pathology scores from analysis of Swiss-rolled H&E stained small 
intestinal sections (n=5/group). Error bars represent 95% confidence intervals about the 
mean score. Groups with different letters differed significantly (P < 0.05). C) 
Representative H&E stained sections of small intestine. D) Ratio of villus height to crypt 
depth taken from small intestinal mucosa. E) % CD11b- and GR--positive cells (i.e., 
neutrophils) in the spleen after 7 days of treatment. F) % CD11b positive and GR-1-
positive cells (i.e., neutrophils) in the mesenteric lymph nodes (MLN) after 7 days of 
treatment.  
 
Figure 1 Indole attenuates severity of NSAID enteropathy.  
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Indole Prevented Indomethacin-Induced Fecal Microbiota Shift and Alterations of the 
Inferred Metagenome 
Because NSAIDs alter the intestinal microbiota, we evaluated the composition 
and diversity of the fecal microbiota in the 4 groups of mice. To adjust for uneven 
sequencing depth among the samples, each sample was rarefied to an even sequencing 
depth of 10,000 reads per sample prior to analysis.  Alpha rarefaction curves and Good’s 
coverage index estimates indicated that over 90% of the species were represented across 
all samples at this sequencing depth (Figure A-1.3). Using analysis of similarities 
(ANOSIM), no significant difference in the unweighted Unifrac distance metric among 
the groups was observed on day 0 (R=0.10; P=0.11); however, by day 7 there was a 
significant difference among the groups (R=0.3007; P=0.0031). Pairwise comparisons 
between groups revealed that a significant difference in the Unifrac distance metric 
existed only between NSAID and control animals (Table 1) and that co- 
administration of indole with indomethacin attenuated this change in the beta diversity 
of the fecal microbiota.  
The primary gram-positive and gram-negative phyla found in murine feces are 
Firmicutes and Bacteroidetes, respectively.[129]  At the phylum level, PCA revealed a 
separation of NSAID-treated mice from the other groups characterized by increase in 
members of the phyla Bacteroidetes in the NSAID-treated animals between day 0 and 
day 7 (Figure 2A and 2B). Interestingly, PCA revealed qualitatively that co-
administration of indole counteracted the increase in Bacteroidetes and instead appeared 
to shift the group closer to the phylum Firmicutes. Based on the results of PCA, we 
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compared the abundance of members of the phyla Firmicutes and Bacteroidetes and 
found no significant difference after treatment with NSAIDs, indole, or their 
combination (Figure A-1.4). At lower taxonomic levels, however, significant differences 
were observed. For example, co-administration of indole with indomethacin prevented a 
decrease in Clostridiales and instead this group had a significant increase in several 
members of the Clostridales order (Figure 2C).  Furthermore, similarity percentage 
(SIMPER) based on the Bray Curtis dissimilarity measure at phylum, order, and family 
levels further confirmed that indomethacin treatment resulted in the gain of members of 
the Bacteroidales S24-7 family, a major family of Bacteroidetes found in murine feces, 
indicating that gain in this family contributed to the dissimilarity between NSAID and 
the other groups.[130] Co-administration of indole prevented this increase in 
Bacteroidales and instead resulted in an increase in Clostridiales with marginal increases 
in several other members of the Firmicutes phyla (Figure 2D).  
PCA of the inferred metagenome revealed clustering and separation of the 
NSAID-treated mice from the other groups (Figure 2E and 2F), although ANOSIM 
based on the Bray Curtis dissimilarity metric indicated this difference was not significant 
(P>0.05). Consistent with the microbiota data, the distance among groups was greatest 
between the NSAID group and the NSAID + indole group. The major up- and down-
regulated inferred functional pathways between NSAID and NSAID + indole groups 
were tabulated (Table A-1.1).  
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A) Principal component analysis (PCA) plots of 16S rRNA sequencing of the fecal microbiota at the phylum level with biplot
overlay and ANOSIM based on the unweighted Unifrac distance metric (located in the lower right quadrant) of the OTU table
from day 0 revealed no significant differences among the groups at day 0. The area of the gray shaded shapes reflects the
variation among individuals in a group. B) Principal component analysis (PCA) plots of 16S rRNA sequencing of the fecal
microbiota at the phylum level with biplot overlay and ANOSIM based on the unweighted Unifrac distance metric (located in
the lower right quadrant) of the OTU table from day 7 reveal that there is a significant difference among the groups at day 7.
After 7 days, the NSAID group is significantly shifted from the other 3 groups, and this shift was associated with a qualitative
increase in the phylum Bacteroidetes and loss of Firmicutes.  C) Abundance of Clostridales from Day 0 (orange) and Day 7
(green) and Bacteroidales Day 0 (white) and Day 7 (black). Clostridiales were significantly increased on Day 7 relative to Day
0 by co-administration of indole with the NSAID indomethacin. D) Mean abundance of several families of Clostridiales at
Day 0 and Day 7 for each of the treatment groups depicting reduction of these families following NSAID therapy but
expansion indole is co-administered. E) PCA plots of inferred metagenome of the fecal microbiota from Day 0. ANOSIM
based on the Bray Curtis distance measure revealed no significant difference among the groups at day 0. F) PCA plots of
inferred metagenome of the fecal microbiota from Day 7. ANOSIM based on the Bray Curtis distance measure revealed that,
consistent with the microbiota data, the NSAID group visually separated from the other groups; however, this apparent
difference was not significant (P > 0.05 by ANOSIM based on Bray Curtis dissimilarity measure).
Figure 2 Indole increases abundance of Clostridiales and prevents NSAID-induced shift of the microbiota and inferred 
metagenome. 
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Co-administration of Indole Prevents the Indomethacin-induced Tryptophan-derived 
Metabolite Disruption in Feces  
We have identified multiple tryptophan-derived metabolites produced by the 
microbiota predicted to be bioactive and exert effects on the host.[91] Given the 
importance of the microbiota in NSAID enteropathy, we chose to examine whether the 
effects of indole on the intestinal epithelium and microbiota (Figure 2) were correlated 
with tryptophan metabolites. No single tryptophan metabolite was significantly 
correlated with fecal calprotectin (data not shown).  Only the metabolite tyramine was 
significantly (P<0.01) correlated with microscopic pathology scores (Table A-1.2). 
Examination of the fecal profile of all tryptophan metabolites using PCA revealed a 
visible separation of the NSAID-treated mice from the remaining groups on day 7, while 
co-administration of indole appeared to prevent this separation, however, ANOSIM of 
the Bray Curtis dissimilarity measure indicated this apparent difference was not 
significant (P=0.55) (data not shown).  Examination of tryptophan metabolite 
concentrations by treatment group revealed a significant increase in tyramine in the 
NSAID group that was attenuated by co-administration of indole (Table 2); moreover, 
several other tryptophan metabolites tended to be increased only in the feces of mice 
treated exclusively with indomethacin, indicating that NSAID treatment caused 
differences that were attenuated by co-administration of indole (Table 2). Relative to 
controls, mice in the indole-only and indomethacin-only groups had significantly more 
indole; although fecal indole concentrations were generally higher in the NSAID + 
indole mice, this difference was not significant.  
 35 
 
 
Table 2 NSAID treatment altered fecal concentrations of tryptophan-derived 
metabolites.  
Group effects of tryptophan-derived metabolites identifying the direction and magnitude 
of change in fecal concentration between Days 0 and 7. Several tryptophan-derived 
metabolites tended to be increased in the NSAID treated mice (5-hydroxytryptamine, 5-
hydroxyindole, indole, serotonin, tyramine). Fecal concentrations of indole increased in 
the groups in which indole was administered.  
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Co-administration of Indole Attenuates NSAID-induced Pro-inflammatory Mucosal 
Transcriptomic Changes 
We performed RNA-Seq of the distal small intestinal mucosa to examine the in 
vivo transcriptomic changes associated with NSAID enteropathy and to gain insight into 
how the co-administration of indole altered gene expression. The Ingenuity Pathway 
Analysis software package was used to identify pathways represented by differentially 
expressed genes.  Several canonical pathways were altered in NSAID-treated mice 
relative to controls (Figure 3A). Several of the pathways that were modulated by NSAID 
administration were either shifted to the opposite direction (i.e., inhibited or activated, 
respectively), or the degree of activation or inhibition was markedly attenuated by co-
administration of indole (Figure 3B).  Moreover, transcription of specific pro-
inflammatory cytokines (interleukin [IL]-1α, IL-1β, TNF, IL-6) and chemokines 
(CXCL1, CXCL3, CXCL2, CXCL5, CCL2, CCL7) was significantly up-regulated in 
NSAID-treated mice; however, when indole was co-administered the degree of up-
regulation was not significantly different than control mice (Figure A-1.5). Based on our 
results, a proposed schema of the interaction of NSAIDs, the host mucosal epithelium, 
the microbiota, and indole is presented (Figure 4). 
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Figure 3 NSAID enteropathy results in upregulation of innate immune response 
pathways and the co-administration of indole regulates this response. 
A) Heatmap showing upregulated (red) and down regulated (blue) pathways in the small 
intestinal mucosa from NSAID-treated mice compared with control animals. B) 2-
column heatmap showing upregulated (red) and down-regulated (blue) pathways in the 
small intestinal mucosa from NSAID-treated mice compared with control mice (left 
column) and NSAID + indole versus control mice (right column). 
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Figure 3 Continued 
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Figure 4 Co-administration of indole with indomethacin attenuates NSAID enteropathy 
and indole may exert these beneficial effects through several possible mechanisms. 
NSAID enteropathy is characterized by a loss of barrier function resulting in an influx of 
luminal contents and a massive innate immune response. Indole is known to have direct 
effects on intestinal epithelial cells including upregulation of tight-cell junctional 
proteins, effects on immune responses including inhibition of NF-κB, and regulating the 
overall innate immune response. Moreover, co-administration of indole with NSAID 
administration resulted in an increase in the abundance of Firmicutes, principally 
Costridales, known to be important in maintaining intestinal homeostasis, and appeared 
to prevent any increase in Bacteroidales. 
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Discussion 
Co-administration of indole attenuated small intestinal mucosal damage induced 
by administration of indomethacin in mice as manifested by reduced microscopic 
pathology and fecal calprotectin concentration. Fecal calprotectin is a well-established, 
non-invasive indicator of intestinal mucosal injury induced by NSAIDs in human 
patients and animal models, and correlates well with 4-day fecal excretion of 
111Indium-labelled leukocytes.[72, 131] The findings of decreased fecal calprotectin 
and decreased microscopic pathology have important clinical implications.  A variety of 
NSAIDs are used widely for an array of clinical conditions ranging from pain-relief for 
minor injuries to management of rheumatoid arthritis or cancer.  The relatively low cost, 
high effectiveness, and lack of alternatives to NSAIDs indicate that their use will 
continue to be highly prevalent.  Consequently, agents that might be co-administered 
with NSAIDs to diminish NSAID enteropathy would be clinically important.  Further 
evaluation of indole to ameliorate NSAID enteropathy in animal models and naturally-
occurring disease is warranted by our findings.  
Administration of NSAIDs increases the proportion of gram-negative organisms 
at the expense of gram-positive organisms in the intestinal microbiota, and this shift has 
been shown to contribute to NSAID-induced intestinal injury.[25, 43, 78] Specifically, 
NSAID administration decreases various members of the class Clostridia and increases 
members of the class Bacteroidia.[41] Mice treated with indole and indomethacin did not 
have a change in the abundance of Bacteroidia but did have an increase in several 
members of the gram-positive family Clostridiales in concert with diminution of the 
 41 
 
severity of intestinal mucosal damage.  Evidence exists that the microbiota plays an 
important role in the development of NSAID enteropathy.  Germ-free rats treated with 
NSAIDs develop less severe enteropathy than specific-pathogen-free rats or germ-free 
rats that have been colonized with gram-negative bacteria.[57] Toll-like receptor (TLR) 
4-deficient mice develop less severe lesions than isogeneic TLR4-competent strains.[25]  
Dramatic NSAID-induced alterations of the gut microbiota are well-documented and 
most often characterized by a loss of gram-positive bacteria with a concurrent increase in 
gram-negative bacteria.[38, 78]  Moreover, this particular shift in the microbiota has 
been associated with increased severity of intestinal mucosal injury, and preventing this 
shift can reduce mucosal injury.[39] The classic indomethacin-induced increase in types 
of Bacteroidia we observed in our study were not significant, but this was likely 
attributable to limited power to detect a statistically significant difference resulting from 
our small sample size. It is not clear why increased abundance of gram-negative bacteria 
worsens the severity of NSAID enteropathy, but direct effects of LPS and the host innate 
immune response to LPS appear to be important.[23, 39] It is also possible that loss of 
beneficial gram-positive bacteria is important.  Commensal Clostridia have been shown 
to be critically important in gut homeostasis, specifically members of Clostridium cluster 
XIVa and Clostridium cluster IV.[132] Interestingly, several members of these 2 
clostridial clusters were increased in the NSAID-treated animals in which indole was co-
administered.  
The host response to the microbiota might be more important than the microbiota 
itself in the pathogenesis of NSAID enteropathy. Neutrophils are key effector cells of 
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innate immunity and are critically important in the pathogenesis of NSAID 
enteropathy.[31, 133] Neutrophils are recruited to the site of injury by the influx of 
luminal contents following increased mucosal permeability. The resident innate immune 
cells present in the epithelium and lamina propria release cytokines and chemokines that 
attract circulating neutrophils. These neutrophils, along with other innate immune cells, 
then release pro-inflammatory cytokines, typically characterized by an abundance of the 
IL-1 super family, TNF-α, IL-6, and others, that are responsible for the damage to the 
lower GI tract.[30, 134] This critical role for neutrophils in NSAID enteropathy is 
supported by our findings of neutrophilic infiltration of both the spleen and MLN 
following NSAID administration and reduced neutrophil concentrations in these tissues 
with co-administration of indole. Our data also affirm the importance of the innate 
immune response in the pathophysiology of NSAID enteropathy because many of the 
most up-regulated pathways identified by RNA-Seq reflected the innate immune 
response (viz., NF-κB pathway, TLR signaling pathways, and the LPS/IL-1 response). 
Moreover, at the individual gene level, several of the classic pro-inflammatory cytokines 
associated with neutrophil activation and known to be important in NSAID enteropathy 
(e.g., TNF-α, IL-1, and IL-6) were up-regulated among NSAID-treated mice.[30, 135, 
136] Co-administration of indole, however, attenuated or reversed up-regulation of 
genes associated with innate immunity and inflammation that contribute to the 
pathogenesis of NSAID enteropathy. In addition, several chemokines that attract 
neutrophils were up-regulated in the NSAID-treated mice and this up-regulation was 
dramatically attenuated by the co-administration of indole. These data indicate that 
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indole can mitigate the host innate immune response to the influx of luminal contents 
across injured epithelia.  Indole has been shown to inhibit NF-κB signaling in intestinal 
epithelial cells.[92] It is thus plausible that indole exerts similar effects on neutrophils 
and other innate immune cells, thereby reducing cytokines dependent upon NF-κB 
signaling. Although NF-κB signaling was activated by administration of both NSAID 
and NSAID + indole, activation of this pathway was greatly diminished by co-
administration of indole with NSAIDs, suggesting indole might mitigate NSAID damage 
in part by inhibiting NF-κB. It is important to note that the mRNA for RNA-seq was 
isolated from mucosal scrapings. These scrapings likely contain epithelial cells as well 
as cells residing in the lamina propria (i.e., immune cells recruited to the inflamed gut 
due to loss of barrier function) and therefore we cannot be sure the exact source of gene 
expression profiles. NSAID enteropathy is characterized as a mucosal injury and we felt 
examining the transcriptome of this location would be more informative than examining 
the transcriptome of whole tissue.[137] The observed anti-inflammatory effects of indole 
may be due to indole’s effects on epithelial cells, immune cells in the lamina propria, or 
both. 
It is unclear how indole prevented the characteristic shifts in the composition of 
the microbiota associated with NSAID administration.  Indole has long been recognized 
as a quorum-sensing molecule so it is possible that indole directly affected the microbial 
community by acting as an intra-kingdom signaling molecule.[102, 103] It is, however, 
also plausible that changes in the microbiota associated with NSAID use occur 
secondary to mucosal inflammation because mucosal inflammation has been shown to 
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alter the luminal environment.[51] Indole might have attenuated mucosal damage, which 
in-turn prevented the expected changes in the microbiota. Finally, it has been shown that 
GI microbiota can vary with environment including cage-dependent variation and cage-
dependent clustering.[138] In order to mitigate this phenomenon, after acclimation and 
immediately prior to starting the study (Day 0), we randomly assigned mice into 
treatment groups and then moved them into cages based on the group to which they were 
randomly assigned.  There were no significant differences in the fecal beta diversity 
among the groups at day 0. It is possible, however, that were some cage-dependent 
microbiota changes that occurred over the 7 days of treatment that might have influenced 
the composition of the microbiota after treatment.  
Indole is present in the GI tract of humans and animals at relatively high 
concentrations (~250-1,100 µM).[139, 140] It has been speculated that, because 
intestinal epithelial cells are continually exposed to indole, indole may act as an 
interkingdom signaling molecule. Indeed we have shown, in vitro, that indole does 
behave in this manner and has anti-inflammatory effects on intestinal epithelial cells and 
upregulates expression of genes associated with tight cell junctions.[92] We therefore 
expected increasing the concentration of indole within the lumen of the GI tract might 
mitigate NSAID enteropathy because of the in vitro effects of indole on intestinal 
epithelial cells. As expected, we observed that mice gavaged with indole (alone or in 
combination with indomethacin) had increased fecal concentration of indole.  
Interestingly, the NSAID-only treated mice also had increased fecal concentrations of 
indole.  Although both gram-negative and gram-positive bacteria produce indole, the list 
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of gram-negative bacteria known to produce indole is much larger than gram-positive 
bacteria.[103] Thus, the observed increase in gram-negative bacteria in the NSAID 
treated mice might explain their increased fecal concentrations of indole.  The beneficial 
effects of indole in this study were observed at the distal small intestine, but the 
concentration of indole and the microbiota diversity were determined using fecal 
samples. Fecal metabolite and microbiota characterization do not always correlate well 
with those of more proximal mucosal locations in the GI tract.[141, 142] Therefore, it is 
possible that indole was present in higher concentrations in the distal small intestine of 
mice treated with NSAID combined with indole compared with mice treated with the 
NSAID alone, thus contributing to the attenuation of NSAID-induced injury by indole 
administration. Interestingly, several tryptophan metabolites that act as neurotransmitters 
including serotonin and 5-hydroxytryptamine were also increased in NSAID-treated 
mice. Hypermotility of the GI tract is induced by NSAIDs and contributes to the 
pathophysiology of NSAID enteropathy.[143, 144] The microbiota shift induced by 
NSAIDs might result in production of prokinetic metabolites that contribute to GI 
hypermotility.  
In summary, indole supplementation of mice attenuates the deleterious effects of 
NSAIDs on the distal small intestine and modulates NSAID-induced alterations in the 
composition of the fecal microbiota. The major events in the onset of NSAID 
enteropathy are intestinal epithelial cell death, increased mucosal permeability, influx of 
luminal contents, and host innate immune response to the microbiota.[43, 145, 146] 
Indole likely reduces intestinal injury induced by NSAIDs at multiple levels, including 
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neutrophilic infiltration, NSAID-induced dysbiosis, and pro-inflammatory pathways in 
the distal small intestine. Future work will focus on interrogating the potential 
mechanisms by which indole exerts this beneficial effect in order to further elucidate 
means to control or prevent NSAID enteropathy. 
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CHAPTER III 
NON-INVASIVE TRANSCRIPTOME IS REFLECTIVE OF TISSUE-LEVEL 
TRANSCRIPTOME IN A MOUSE MODEL OF NSAID ENTEROPATHY 
 
Introduction 
Non-steroidal anti-inflammatory drugs (NSAIDs) are among the most frequently 
consumed pharmaceuticals worldwide because of their anti-inflammatory, anti-
neoplastic, and analgesic effects. Their use, however, can result in an enteropathy that 
has an alarmingly high rate of morbidity and mortality.  In the United States alone, 
NSAID enteropathy results in approximately 100,000 hospitalizations and 16,500 deaths 
each year [98]. An additional 2/3 of both short- and long-term NSAID users develop 
subclinical or undiagnosed distal small intestinal lesions [99]. Although detection and 
management of NSAID-induced lesions of the proximal GI tract (i.e., gastropathy) have 
been well documented, diagnosis and treatment of NSAID-induced damage of the GI 
tract distal to the duodenum (also known as NSAID enteropathy, affecting primarily the 
distal jejunum and ileum) remains elusive [96, 97]. The incidence of NSAID enteropathy 
is expected to increase due to greater use of NSAIDs for the treatment of rising numbers 
of inflammatory conditions, by the aging population of North America, and for their 
anti-neoplastic effects [147]. The lower GI tract of multiple mammalian species is 
affected by NSAIDs in a similar manner in terms of location and type of injury, and 
magnitude of the clinical complications [148-150].  
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The pathophysiology of NSAID enteropathy is complex and poorly understood 
[100]. It has been proposed to involve deleterious effects of NSAIDs on the intestinal 
mucosa including enterocyte cell death, increased mucosal permeability, and interaction 
of the damaged mucosa with luminal contents including bacteria (GI microbiota) and 
bacterial products or components such as lipopolysaccharide (LPS) [97, 137]. The 
resulting inflammatory cascade is mediated by the innate immune response to LPS and 
several pro-inflammatory cytokines including tumor necrosis factor (TNF), interleukin 
(IL)-1, and IL-6 [25, 151, 152]. The GI microbiota has recently been implicated as an 
important contributor to NSAID enteropathy, with the host-microbiota interaction 
playing a critical role in the pathophysiology of NSAID enteropathy although the exact 
mechanisms remain to be elucidated [23, 39, 42, 49, 78].  
An important limitation to understanding the pathogenesis of NSAID enteropathy 
(and other gastrointestinal disorders) is the difficulty in obtaining longitudinal 
(sequential) data from individuals regarding intestinal function and health. Great clinical 
and investigative need exists for the development of non-invasive methods to 
characterize the health and function of the GI tract distal to the stomach to more 
effectively identify, study, and manage NSAID enteropathy (and other intestinal 
mucosal disorders).   
Up to 1/3 of human colonic epithelial cells (up to 1010 cells in an adult) are 
exfoliated and shed in feces each day [153]. Isolation and sequencing the mRNA (host 
transcriptome) from exfoliated intestinal epithelial cells (IECs) has been validated in the 
context of colon carcinogenesis in rats and humans, and in characterizing human 
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neonatal gastrointestinal development [154-158]. Exfoliated IECs, however, have not 
been utilized to evaluate the small intestine. The exact number of cells exfoliated from 
the small intestinal mucosa in human stool is unknown, and it is thus unknown whether 
evaluating the exfoliated cell transcriptome of feces can be informative and accurate for 
small intestinal lesions.  Thus, the objective of this study was to determine whether 
exfoliated IECs could be a suitable non-invasive approach for identifying and studying 
NSAID enteropathy in a murine model. Specifically, we performed RNA-Seq on both 
small intestinal mucosa and exfoliated IECs in feces. We then applied novel 
computational approaches, e.g., linear discriminant analysis (LDA) and sparse canonical 
correlation analysis (CCA), to analyze the inter-relatedness of these data. The goals of 
these studies were: 1) to determine whether the transcriptome of exfoliated IECs is 
reflective of that of the small intestinal mucosa; 2) to demonstrate that the transcriptome 
of exfoliated IECs can be used to differentiate healthy and diseased phenotypes; and, 3) 
to generate hypotheses regarding key biological pathways and processes involved in the 
pathogenesis of NSAID enteropathy.   
Materials and Methods 
Animals and Sample Collection 
Animal protocols were approved by the Texas A&M Institutional Animal Care 
and Use Committee in accordance with appropriate institutional and regulatory bodies’ 
guidelines. Animals were handled and treated as previously described [32]. Briefly, 
eight- to 10-week-old specific-pathogen-free C57BL/6J mice were purchased and 
allowed to acclimate for 2 weeks. Mice were fed standardized laboratory rodent diet and 
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sterile water ad libitum. Mice were randomly divided into the following 4 groups (n=5 
mice/group): 1) NSAID (indomethacin); 2) indole; 3) NSAID + indole; and, 4) untreated 
controls.  Mice were then rehoused on the basis of treatment group assignment, with 5 
animals/group-cage. To induce NSAID enteropathy, mice in group 1 were gavaged once 
daily with indomethacin (5 mg/kg; for 7 days; Sigma Aldrich, St. Louis, MO) dissolved 
in DMSO (Sigma Aldrich, St. Louis, MO) and further diluted in phosphate buffered 
saline (PBS). Mice in group 2 received indole by gavage (20 mg/kg; once daily for 7 
days; Sigma Aldrich, St. Louis, MO) dissolved in sterile water warmed to 55°C. Mice in 
group 3 received indole co-administered with indomethacin by gavage at the dosages 
described above.  All mice were gavaged with equal volumes (200 μL) and equal 
concentrations of DMSO (0.001%). Feces were collected daily by placing individual 
animals in sterile plastic cups that were RNase- and DNase-free until they passed feces. 
The mice were immediately returned to their home cages and the feces immediately 
flash frozen at -80°C. 
Extraction of mRNA from Exfoliated Intestinal Epithelial Cells and Library Preparation 
PolyA+ RNA was isolated from stool samples from mice similarly as previously 
described [158, 159]. Each mouse sample was processed with the NuGEN Ovation 3′-
DGE kit (San Carlos, CA) to convert RNA into cDNA followed by NuGEN Encore 
Rapid Library kit to create Illumina libraries, as per manufacturer's instructions. 
Sequencing on Illumina HiSeq 2500 platforms (San Diego, CA) were carried out using 
standard Illumina protocols. Briefly, 30 ng of each sample were used to synthesize first 
and second strand cDNA, which was purified using Agencourt RNAClean XP beads 
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(Brea, CA) included in the kit. The cDNA was linearly amplified using the NuGEN 
SPIA primer, and cDNA quality and quantity were determined using an Agilent 2100 
Bioanalyzer and Nanodrop spectrophotometer. Two micrograms of cDNA were 
fragmented using a Covaris S2 sonicator with the following settings: duty cycle 10%, 
intensity 5, cycles/burst 100, time 5 min. Fragmented samples were concentrated using 
the MinElute Reaction Cleanup kit (Qiagen, Venlo, Netherlands) as per manufacturer's 
instructions. Samples were quantified using the Nanodrop.  Following cDNA fragment 
repair and purification, Illumina adaptors were ligated onto fragment ends followed by 
amplification to produce the final library. Libraries were quantified using the Kapa 
Library Quantification kit (Kapa Biosystems) and run on an Agilent DNA High 
Sensitivity Chip to confirm appropriate sizing and the exclusion of adapter dimers.  
Tissue mRNA Extraction and Library Preparation 
RNA was extracted from ileal mucosal scrapings using an RNeasy mini kit 
(QIAGEN, Redwood City, CA) following the manufacturer’s instructions and including 
on-column DNase treatment.  RNA quantity was determined using a Nanodrop 
spectrophotometer (Fisher Thermoscientific) and the quality was assessed using the 
Nano6000 chip on a Bioanalyzer 2100(Agilent Technologies). Only RNA with an 
integrity number (RIN) > 8 was used. The samples were randomized prior to RNA-Seq 
library preparation.  Sequencing libraries were made using 250 ng of RNA and the 
TruSeq RNA Sample Preparation kit (Illumina) following the manufacturer’s 
instructions.  A volume of 2.5 µl of ERCC spike-in RNA control mix (Life 
Technologies) was added to the starting RNA at a dilution of 1:1000.   
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RNA Sequencing and Downstream Processing 
Libraries were pooled and sequenced on an Illumina HiSeq 2500 at the Texas 
AgriLife Genomics and Bioinformatics Services Core Facility (College Station, TX). 
Sequence data were uploaded into NCBI small reads archive (Accession number 
PRJNA290483).  Sequencing data were provided in a de-multiplexed format and aligned 
using Spliced Transcripts Alignment to a Reference (STAR) software with default 
parameters and referenced against the genome of Mus musculus (Ensembl version 
GRCm38) [106]. Differentially expressed genes were determined using EdgeR based on 
the matrix of gene counts [107]. Gene pathway involvement and intersections were 
analyzed using QIAGEN’s Ingenuity ® Pathway Analysis (IPA, QIAGEN, Redwood 
City, CA http://www.qiagen.com/ingenuity) by uploading appropriate gene lists with 
fold change and false discovery rate (FDR) P-values. 
 Sparse Canonical Correlation Analysis (CCA) 
In order to take into account the multivariate structure when assessing and 
ranking genes, we analytically quantified the multivariate relationships between the 
exfoliated cell and tissue transcriptomic data sets.  Sparse CCA provides measures of the 
strength of multivariate association between variable sets as well as a means to interpret 
the role of variables in terms of the underlying multivariate relationship [157]. Briefly, 
for the two random vectors x = (𝑥1, 𝑥2, … , 𝑥𝑝)
𝑇 and y = (𝑦1, 𝑦2, … , 𝑦𝑞)
𝑇 CCA aims to 
find two projection directions 𝑢1 ∈ ℝ
𝑝 and 𝑣1 ∈ ℝ
𝑞 so that 
(𝑢1, 𝑣1) = argmax
𝑢,𝑣
 Corr(𝑢𝑇𝑥, 𝑣𝑇𝑦) = argmax
𝑢,𝑣
𝑢𝑇Σ𝑥𝑦𝜈
√(𝑢𝑇Σ𝑥𝑥𝜈)(𝑣𝑇Σ𝑦𝑦𝜈)
, 
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where, Σ𝑥𝑦, Σ𝑥𝑥, Σ𝑦𝑦 are covariance and variance matrices. Let 𝑋 and 𝑌 denote 𝑛 ×
𝑝 and 𝑛 × 𝑞 data matrices as the observations from random vectors 𝑥 and 𝑦, 
respectively. Then the empirical version of the above objective function can be written 
as 
max
𝑢,𝑣
  𝑢𝑇𝑋𝑇𝑌𝑣
subject to  𝑢𝑇
𝑋𝑇𝑋
𝑛
𝑢 = 1, 𝑣𝑇
𝑌𝑇𝑌
𝑛
𝑣 =  1.
 
This objective function, however, does not have closed-form solution when the sample 
size 𝑛 is less than min(𝑝, 𝑞). In addition, the result does not perform variable selection 
and hence usually lacks biological interpretability. To overcome these limitations the 
sparse CCA adds a regularization conditions to obtain the sparse solution with a 
reduced the computational cost as previously described [160-162]. The main idea of 
this approach is to utilize 
max
𝑢,𝑣
  𝑢𝑇𝑋𝑇𝑌𝑣
subject to  𝑢𝑇𝑋𝑇𝑋𝑢 ≤ 1, 𝑣𝑇𝑌𝑇𝑌𝑣 ≤ 1
∥ 𝑢 ∥1≤ 𝑐1, ∥ 𝑣 ∥1≤ 𝑐2,
 
where the tuning parameters 𝑐1, 𝑐2, are positive. It has been shown that in high-
dimensional problems, treating the covariance matrix as a diagonal one yields 
satisfactory results [160,161]. Thus, 
max
𝑢,𝑣
  𝑢𝑇𝑋𝑇𝑌𝑣
subject to  ∥ 𝑣 ∥2≤ 1, ∥ 𝑢 ∥2≤ 1,
∥ 𝑢 ∥1≤ 𝑐1, ∥ 𝑣 ∥1≤ 𝑐2,
 
yields the first pair of sparse canonical correlation loadings. The algorithm to solve this 
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optimization problem uses soft-thresholding, binary search, and finds the second pair of 
sparse canonical correlation components via the deflation method [160,163]. In our 
implementation of the sparse CCA method, a pair of tuning parameters  (𝑐1, 𝑐2) with 
values between 0 and 1 were utilized. To select the tuning parameters, the leave-one-
out cross validation was used. Specifically, a grid of dense values from (0,1) × (0,1) 
were used as potential values of (𝑐1, 𝑐2) and the absolute value of correlation without 
penalty was calculated as the criterion function in a cross validation method. 
Linear Discriminant Analysis (LDA) 
We used the edgeR output of genes differentially expressed between NSAID and 
control animals with false discovery rate (FDR) P value of less than 0.05 for feature set 
identiﬁcation. Subsequently, we used a previously described method to determine, 
within the differentially expressed genes, which genes (1-feature) or pairs of genes (2-
feature) accurately discriminated NSAID treated animals from control animals as given 
by the classification error rates [155]. Estimation of the classiﬁcation error is of critical 
importance when the number of potential feature sets is large. When sample size is 
limited, an error estimator may have a large variance and, therefore, may often be low, 
even if it is approximately unbiased. This can produce many feature sets and classiﬁers 
with low error estimates. In this case, the problem was mitigated by applying a bolstered 
error estimation technique that has been previously described.[155, 164] The result of 
this approach is a list of feature sets (1 and 2-feature) that are ranked with respect to their 
bolstered classiﬁcation error estimates. 
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Results 
Data Pre-processing and Normalization 
RNA sequencing reads for mucosal scrapings and exfoliated IEC’s mapped to 
25,907 genes and 22,783 genes, respectively. Genes present in low abundance (i.e., ≤ 4 
animals or ≤ 20 times) across all samples, were removed from both datasets and the 
remaining genes subjected to downstream analysis. This reduced the number of 
transcripts for downstream analysis in the exfoliated IEC data-set to 13,884 genes and 
mucosal scrapings to 19,255 genes. Although the total number of genes in the tissue 
were reduced by 16% and in the exfoliated IEC data by 39% due to filtering, the total 
number of reads was negligibly affected (tissue reduced from 520,911,030 reads across 
all samples to 520,870,404 – a 0.008% reduction; exfoliated IEC data reduced from 
59,406,107 to 59,338,338 – a 0.001% reduction). Total gene counts and the number of 
reads/gene obtained for each sample of the raw, filtered data for both tissue and 
exfoliated IEC data-sets are shown (Figure 5a-d. Given the apparent between-sample 
variation in total mapped reads (Figure 5b), especially as compared with the tissue data, 
we investigated if this was due to differences in library size. Examination of the relative 
abundance of 500 murine house-keeping genes in each sample indicated that indeed, 
differences in between-sample total counts were represented by similar magnitudes of 
differences in abundance of these 500 house-keeping genes (Figure 5e).   
 
 56 
 
 
Figure 5 Exfoliated IEC reads exhibit more between sample variation than mucosal reads.  
A) Total gene counts after filtering for each sample across all treatment groups from the sequenced RNA extracted from the 
tissue. B) Total gene counts after filtering for each sample across all treatment groups from the sequenced RNA extracted from 
the exfoliated IECs. C) log(2) counts per gene per sample across all treatment groups from the sequenced RNA extracted from 
the tissue after filtering. D) log(2) counts per gene per sample across all treatment groups from the sequenced RNA extracted 
from exfoliated IECs after filtering. E) log(2) total gene reads of 500 murine house-keeping genes (black) and all other genes 
(purple) from the exfoliated IEC data after filtering
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To account for between-sample differences in read-counts (i.e., sequencing 
depth) RNA-seq data was normalized with edgeR accounting for group effects using the 
function calcNormFactors and the upper-quartile method. Total gene-counts and 
boxplots of the number of reads/gene for each sample of the normalized data for both 
tissue and exfoliated cell data sets are shown (Figure 6a-d). Variability in abundance of 
post-normalization total house-keeping genes was also improved (Figure 6e). Biological 
variability in the exfoliated IEC data was assessed by plotting the biological coefficient 
of variation (BCV) versus the mean log counts per million (CPM) and multi-dimensional 
scaling (MDS) plots were used to visually assess the similarity of the samples within 
each treatment group (Figure A-2.1). These results demonstrate a relatively high degree 
of variation among the exfoliated IEC data (common dispersion 0.6548 and BCV 
0.8012) (Figure A-2.1a) with no visually apparent differences among the groups (Figure 
A-2.1b). The common dispersion and BCV were slightly improved by normalization 
(common dispersion = 0.59188 and BCV = 0.7693) and group effects were unchanged 
(Figure A-2.1c, d). The biological variance in these data was much higher than in the 
tissue samples with a post-normalization common dispersion of 0.14334 and BCV of 
0.3786 (Figure A-2.1e, f).  
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Figure 6 Raw data after filtering and normalization show that the between sample variation in exfoliated IEC reads are 
improved and similar to tissue reads.  
A) Total gene counts after filtering and normalization for each sample across all treatment groups from the sequenced RNA 
extracted from tissue. B) Total gene counts after filtering and normalization for each sample across all treatment groups from 
sequenced RNA extracted from exfoliated IECs. C) log(2) counts per gene per sample across all treatment groups from 
sequenced RNA extracted from tissue samples after filtering and normalization. D) log(2) counts per gene per sample across 
all treatment groups from sequenced RNA extracted from exfoliated IECs after filtering and normalization. E) log(2) total gene 
reads of 500 murine house-keeping genes (black) and all other genes (purple) from the exfoliated IEC data after filtering and 
normalization. 
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 Exfoliated IEC Transcriptome is Reflective of the Tissue-level Transcriptome 
We next examined the similarities and differences in the gene expression profiles 
from exfoliated cells compared with those from the scraped intestinal mucosa. Gene lists 
were uploaded into IPA and the intersection of various gene lists were calculated. We 
initially examined the intersection of genes represented in the 2 most divergent treatment 
groups (NSAID-treated and control). The Venn diagram (Figure 7a) shows the 
intersection of all genes represented in these datasets.  Approximately, 96% of all genes 
that were mapped from the exfoliated IEC RNA were also present in the tissue-level 
RNA. Similarly, 77% of genes that were mapped from the tissue-level RNA were 
present in the exfoliated IEC RNA. We then mapped these gene lists to pathways 
according to IPA’s ingenuity knowledge base.   Both datasets (i.e., tissue and exfoliated 
IEC) exhibited similar occupancy and predicted directionality (z-score) (Figure 7b, c). 
Figure 8b shows the canonical pathways to which the differentially expressed genes 
between control and NSAID-treated animals were mapped.  In addition, Figure 3c shows 
the predicted upstream regulators represented by the same comparisons and again 
colored by predicted activation and inhibition. The visual similarity and high correlation 
of these pathways and the directions of their activation are shown in Figure 7. In 
addition to the apparent visual agreement a quantitative correlation was also observed. 
The Pearson correlation coefficient of the Z scores of the upstream regulators was 0.769 
with a P value < 0.0001. For the canonical pathways, the Pearson correlation coefficient 
was (0.537) and significant (P = 0.0022).  
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Initial visual inspection of the global transcriptomic heat maps (Figure 7b, c) and 
quantitative data suggests a strong correlation between the exfoliated IECs and the 
tissue. To further examine the interdependent relationship between these 2 profiles, we 
utilized sparse CCA, a novel multivariate statistical analysis approach. Sparse CCA is a 
dimensionality reduction technique that identifies the fewest numbers of genes that show 
the greatest amount of correlation between data sets according to specific optimality 
criteria. Although the sparse CCA plots should not be assigned any particular biological 
interpretation, they could be considered a stringent method for determining correlation 
of large data sets.[161] Sparse CCA plots positioned by 1st and 2nd component scores 
from the exfoliated IECs and colored by the 1st component tissue scores (Figure 8a) 
closely mirrored sparse CCA plots positioned by 1st and 2nd component scores from the 
tissue and colored by 1st component scores from exfoliated cells (Figure 8b). These 
similarities are also revealed when specifically examining the boxplots of these scores 
across data sets where the same patterns of scores between the groups are present in both 
the exfoliated IEC and intestinal mucosa data (Figure 8c, d).  Taken together, these data 
indicate that the global transcriptome profiles from exfoliated intestinal epithelial cells 
reflect and correlate well with the transcriptome profile of the distal ileum.
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Figure 7 The exfoliated IEC transcriptome is similar to the tissue transcriptome as shown by similar gene lists and pathways. 
A) Venn diagram of the intersection of the list of genes found in exfoliated cells and gene list found in the tissue. B) Heat map 
of the Z-scores of the canonical pathways to which the differentially expressed genes between control and NSAID-treated 
animals were mapped from the tissue (left column) and the exfoliated cells (right column). C) Heat map of the Z-scores of the 
upstream regulators to which differentially expressed genes between control and NSAID-treated animals were mapped from 
the tissue (left column) and the exfoliated cells (right column). 
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Figure 8 Sparse canonical correlation analysis (CCA) reveals the global transcriptome profiles from exfoliated intestinal 
epithelial cells correlates well with the transcriptome profile of the distal ileum. 
A) Sparse CCA plots positioned by 1st and 2nd component scores from the exfoliated IECs and colored by the 1st component 
tissue scores. B) sparse CCA plots positioned by 1st and 2nd component scores from the tissue and colored by 1st component 
scores from exfoliated cells. C) Boxplots of the sparse CCA scores (first and second component) from exfoliated cells for each 
treatment group. D) Boxplots of the sparse CCA scores (first and second component) from tissue for each treatment group. 
 
 64 
 
 
 65 
 
 
Transcriptome of Exfoliated IECs Classifies Healthy and Diseased Phenotypes 
In order to derive biological meaning from the tissue and exfoliated cell data-
sets, we performed a series of data reduction techniques. Linear discriminate analysis 
was performed on the counts of genes, from exfoliated IECs, identified as being 
differentially expressed between indomethacin-treated and control animals. There were 
691 genes identified as being differentially expressed between these treatment groups, 
and 1-feature (i.e., single gene) LDA identified 50 of these genes as being able to 
classify NSAID and non-NSAID treated animals with less than 5% resubstituted error 
rate, the top 20 are shown (Table A-2.1). [164] These genes were subsequently uploaded 
into IPA along with their respective P-values and fold-changes in order to determine 
which pathways and upstream regulators identified by LDA are best suited to classify 
NSAID versus control animals with respect to all differentially expressed genes. The top 
(lowest P-value) upstream regulators and the networks to which these genes belong are 
shown (Table A-2.2 and Figure A-2.2 a, respectively). As previously shown, a 
substantial decrease in classification error was observed when pairs of genes (i.e., 2-
feature-based LDA) were used to discriminate NSAID from control animals (Table A-
2.3) [155]. We speciﬁcally queried the data with respect to pairs of genes that performed 
better than either of the genes individually in order to identify sets of genes that perform 
in a multivariate manner to provide strong classiﬁcation (Table A-2.4). These genes 
were subsequently uploaded into IPA along with their respective P-values and fold-
changes in order to determine which pathways and upstream regulators provide strong 
classification in a multivariate manner (Figure A-2.2 b and Table A-2.5).  
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Analysis of Exfoliated IEC Transcriptome Generates Hypotheses Regarding the 
Pathophysiology of NSAID Enteropathy and its Clinical Management 
From our study that first reported indole regulation of host cell function, we 
extended these findings to a model of intestinal damage and inflammation to 
demonstrate that the co-administration of indole attenuated the severity of GI injury 
associated with NSAID use [32, 92]. The mechanism by which indole exerted this effect, 
however, was unclear. The major effects of indole based on the tissue-transcriptome 
appeared to be mediated by a reduction of the innate immune response via alterations in 
the gut microbiota [32]. Because the exfoliated IEC and tissue-level gene expression 
profiles were similar (Figure 7 and Figure 8), we sought to examine the differences in 
the exfoliated IEC transcriptome between control versus indomethacin-treated animals 
and control versus indole+indomethacin-treated animals. For this purpose, the top 40 
canonical pathways altered in exfoliated IECs were sorted based on differences in Z-
scores between the 2 treatments (Figure 9a). Similarly, the top 50 upstream regulators 
altered in exfoliated IECs are shown in Figure 9b. While these data reveal pathways 
consistent with reduced inflammation, as has been shown previously, it is unclear how 
this anti-inflammatory effect occurred and which of these upstream regulators mediate 
indomethacin induced GI injury and the protective effects observed by the co-
administration of indole. To address this question, we mapped the network of the top 15 
upstream regulators identified by our novel data reduction approach and analysis of 2-
feature LDA in the context of NSAID vs control animals (Figure 10a). We then overlaid 
the fold change and false discovery rate (FDR) P-values of these same molecules from 
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the analysis of control versus NSAID+indole (Figure 10b) and identified which of these 
molecules were altered (opposite fold-change either realized or predicted). This resulted 
in the identification of 11 genes that were altered between NSAID administration and 
NSAID+indole administration. We subsequently uploaded these genes into IPA in order 
to determine plausible pathways by which indole attenuated NSAID-induced GI injury 
(Figure 11). 
To further derive biologically relevant information from the sparse CCA dataset 
(i.e., the list of genes that explain the greatest amount of correlation between exfoliated 
IEC transcriptome and tissue-level transcriptome), we uploaded fold-change and FDR P-
values from the comparison of NSAID-treated animals to control animals into IPA as 
previously described [165]. The networks of canonical pathways represented by these 
genes are shown (Figure A-2.3).  Interestingly, 5 of the 17 pathways to which these 
genes belong were associated with cytoskeletal signaling and the interaction of host cells 
with the extracellular matrix. As expected, the remainder of these pathways were 
primarily related to inflammatory responses (i.e., loss of barrier function and influx of 
lumenal contents).    
 
68 
Figure 9 Co-administration of indole reduces inflammatory pathways in NSAID 
enteropathy. A)Heat map of the Z-scores of the canonical pathways to which the 
differentially expressed genes between control vs. NSAID-treated animals (left 
column) and control vs. NSAID+indole (right column) were mapped. B) Heat map of 
the Z-scores of the upstream regulators to which the differentially expressed genes 
between control vs. NSAID-treated animals (left column) and control vs. NSAID
+indole (right column) were mapped.
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Figure 9 continued 
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Figure 10 Noninvasive identification of 6 key genes altered between NSAID and NSAID + Indole treatments. 
A) Network of the top 15 upstream regulator, identified by 2-feature LDA in the context of NSAID vs control animals with 
FDR P-values and fold changes overlaid. B) Same network with P-values and fold changes of NSAID+indole overlaid reveal 6 
genes that were altered (opposite fold-change either realized or predicted) by the co-administration of indole. 
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Figure 11 Pathways identified using the exfoliated IEC transcriptome and two-feature LDA.  
The darker color correlates with lower P-value. 
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Discussion 
Here we have shown that the transcriptome of exfoliated IECs closely resembles 
that at the tissue level in a murine model of NSAID enteropathy. Using RNA-Seq, we 
compared the exfoliated IEC transcriptome to the tissue transcriptome from samples 
obtained from mucosal scrapings of the mouse ileum, the region of the GI tract most 
severely affected in NSAID enteropathy in both mice and human subjects [29, 124, 166-
168]. Although gene expression of exfoliated IECs has been used to examine GI 
development in neonates and for biomarkers of colorectal cancer, we show for the first 
time the application of this approach to examine a disease that primarily affects the small 
intestine [25, 32, 49, 99, 100]. The use of exfoliated IEC mRNA presents several 
important advantages relative to mRNA obtained from the standard approach of tissue 
biopsy. First, use of fecal samples is non-invasive and results in no physical pain to the 
patient. Second, greater requirement of time, effort, and cost is required for collection of 
biopsy specimens than for collection of feces.  Third, although the primary area of injury 
with NSAID enteropathy is the distal small intestine, NSAIDs can affect both the large 
and small intestine of humans and other animals [169, 170]. Exfoliated IECs arise from 
both the colon and small intestine and thus provide an overview of the gene expression 
profiles of the entire gastrointestinal tract, whereas a tissue specimen only provides a 
site-specific gene expression profile [155]. Fourth, intestinal biopsies generally can be 
collected once (typically at a terminal stage of the study), whereas feces can be collected 
sequentially, thereby allowing the temporality of gene expression profiles from 
exfoliated IECs to be used to investigate and monitor disease progression.  
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In general, the exfoliated IEC transcriptome correlated well with the tissue 
transcriptome as evidenced by the intersection of genes present in both datasets, 
similarities of the pathways and processes of the genes and gene regulators, and results 
of sparse CCA analysis. These results are interesting because much of the RNA 
extracted from exfoliated IECs undoubtedly originates from the colon and we did not 
attempt to identify the precise source of these cells.  Nonetheless, we have demonstrated 
that the exfoliated IEC data closely mirrors that of the ileal mucosa, indicating that 
studying IECs can yield informative results about the distal small intestine irrespective 
of knowledge of their precise source.  Further investigation of the impact of concomitant 
colonic disease and other potential confounding factors on use of the IEC transcriptome 
is merited. 
After demonstrating that the exfoliated IEC transcriptome reflects that of the 
mucosa of the distal small intestine, we used the IEC gene expression data to examine 
which pathways and processes were induced by NSAID enteropathy and the 
mechanism(s) by which the microbiota-derived metabolite indole ameliorated the 
severity of NSAID-induced GI injury [32]. Our results further substantiate the 
importance of innate immune responses in NSAID enteropathy [26, 171]. Specifically, 
and as reported previously, we identified several pro-inflammatory pathways and 
upstream regulators including IL-8 (mouse homologs), IL-17, NF-KB, IL-1, and 
MYD88 involved in NSAID enteropathy [25, 26, 124, 133, 171]. The consistency of our 
results based on using IECs with those of prior studies adds evidence to the validity of 
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using this novel approach for the study of NSAID enteropathy (and potentially numerous 
other small intestinal disorders).   
Previously, we identified tryptophan metabolites, including indole, as an 
important class of GI microbiota-derived compounds [172]. We subsequently 
demonstrated that indole protected mice from indomethacin-induced enteropathy [32]. 
The specific molecular mechanism by which indole protects mice from NSAID 
enteropathy, however, remains to be clarified. Therefore, in addition to examining 
biological pathways and processes critical to NSAID enteropathy we also examined the 
exfoliated IEC transcriptome to assess alterations induced by the co-administration of 
indole. Although a number of pathways appear to be involved, our data highlight T-
helper cell differentiation, IL-8 signaling (based on mouse homologs), cytoskeletal 
pathways, and inflammatory pathways as key contributors (Figure 7). Interestingly, 
dietary indoles including indole-3-carbinol and 3,3’-diindolylmethane have been shown 
to influence T-helper cell differentiation primarily by inducing anti-inflammatory T-
regulatory cells [162, 173]. In addition, indole has been shown to inhibit NF-κB 
pathways, specifically LPS-induced IL-8 inflammation and TNF-α pathways in IECs 
[92]. Indole has also been shown to influence various cytoskeletal structures including 
tight-cell junctions and tubulin polymerization [101, 174]. Moreover, the anti-
inflammatory effects of indole, indole-3-carninol, and indole-3-aldehyde have been 
repeatedly demonstrated, although the molecular mechanisms remain to be defined [32, 
93, 101, 175]. One potential mechanism that might be involved is engagement of the aryl 
hydrocarbon receptor (AhR). Ligands of AhR have anti-inflammatory effects in various 
 75 
 
models of colitis including the production of IL-22 [176-178]. Indeed, indole can serve 
as an AhR ligand in the context of IECs and this might, in part, explain indole’s 
attenuation of inflammation in NSAID enteropathy [179-181]. Our unique finding that 
results of analysis of the exfoliated IEC transcriptome are consistent with our reports on 
the known in vitro and in vivo biological effects of indole further supports the concept 
that this novel approach will be an invaluable tool for studying NSAID enteropathy and 
other GI diseases in a non-invasive manner.   
There were several limitations to this study. First, the evaluated sample size was 
small and consisted of a single time-point (day 7). Despite the small sample size, we 
clearly demonstrated that the exfoliated IEC transcriptome reflects that of the tissue at 
the level of the ileum. In addition, our approach revealed the importance of several 
pathways involved in both NSAID enteropathy and the effect of the co-administration of 
indole on this phenotype. Importantly, many of the highlighted pathways are known to 
mediate NSAID enteropathy and are consistent with the anti-inflammatory effects of 
indole. Therefore, even with a small sample size, we were able to recapitulate known 
biologically relevant findings with this technique. In the latter or more severe stages of 
NSAID enteropathy, the major pathways involved are the host response to increased 
mucosal permeability. Therefore, to better understand the temporal events contributing 
to NSAID enteropathy, a more appropriate approach may be to examine earlier time 
points.   
In summary, we have demonstrated that the exfoliated IEC transcriptome closely 
mirrors the transcriptome of the tissue at the level of the ileum. Although this approach 
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has been described previously, this is the first time these findings have been correlated to 
the tissue-level transcriptome. In addition, this technique has not been utilized to 
examine a disease that primarily affects the small intestine. We have shown that the 
exfoliated IEC transcriptome can be a useful tool to examine NSAID enteropathy and 
potentially extend to a number of other GI diseases, including those that affect the small 
intestine. Additionally, the application of noninvasive exfoliated cell based techniques 
might be useful for the early identification and monitoring of therapeutic interventions 
targeting NSAID enteropathy and other small intestinal disorders.   
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CHAPTER IV 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
Conclusions 
As mentioned throughout this dissertation non-steroidal anti-inflammatory drugs 
(NSAIDs) are among the most frequently used pharmaceuticals in the world and yet 
cause enteropathy in an alarmingly high percentage of individuals using this class of 
medications. Importantly, the underlying mechanisms by which NSAIDs induce 
enteropathy are ill-defined and the diagnosis is difficult and typically not made until 
latter stages of progression. The microbiota-host interaction appears to play an important 
role in the pathophysiology of NSAID enteropathy. Although much work remains our 
work here has identified several important aspects of this disease. Namely, we have 
generated the first in vivo work documenting the NSAID induced alterations of the 
mucosal transcriptome. In addition, our work joins the growing body of evidence 
implication host-microbiota interactions in NSAID enteropathy. Specifically, we 
demonstrate the NSAIDs alter the fecal microbiota in a murine model of NSAID 
enteropathy AND show that co-administration of a microbiota-derived metabolite 
attenuates disease severity. These findings suggest that one possible mechanism by 
which the microbiota influences disease severity is alteration of the microbiota-derived 
metabolites (i.e., the metabolome). Indeed, we demonstrate that co-administration of a 
specific microbiota-derived metabolite, indole, not only attenuated disease severity but 
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simultaneously prevented NSAID-induced dysbiosis and alterations of the fecal 
metabolome.   
We then extended this work by examining the exfoliated cell transcriptome in 
this model in order to determine if the transcriptome of exfoliated intestinal epithelial 
cells (IECs) found in the stool could be reflective of NSAID enteropathy, thereby 
allowing longitudinal comparisons of fecal microbiota diversity and host intestinal 
mucosal transcriptome. A second objective was to determine how the microbiota-derived 
metabolite indole, which has been shown to protect against NSAID-enteropathy, altered 
the exfoliated IEC transcriptome. We compared exfoliated cell datasets and tissue-level 
datasets using well-described and novel computational approaches including linear 
discriminant analysis (LDA) and sparse canonical correlation analysis (CCA) to assess 
their inter-relatedness. This allowed us to demonstrate, for the first time, that the 
(noninvasive) fecal exfoliated cell and (invasive) small intestine-scraped mucosa global 
transcriptomes are highly correlated.  These novel findings highlight important pathways 
involved in NSAID enteropathy and the mechanisms by which microbiota-derived 
metabolites protect the host from injury.  Approximately 96% of all genes that were 
mapped from the IEC RNA were also present in the tissue-level RNA. Moreover, the 
pathways represented by these genes and their directional changes were similar in both 
the small intestinal mucosa and exfoliated IEC transcriptome. Specifically, innate 
immune response and pro-inflammatory pathways appeared to be critical in the 
pathophysiology of NSAID-induced enteropathy and indole attenuated severity of injury 
in this model via these pathways. These novel findings highlight important pathways 
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involved in NSAID enteropathy and the mechanisms by which microbiota-derived 
metabolites protect the host from injury. 
Future Directions 
Future directions for continuation of this work include specifically testing 
hypotheses regarding the novel pathways and biological processes identified as being 
critically important in NSAID enteropathy. In addition, confirming the exact mechanism 
by which indole exerted its beneficial effects in these phenotype remains an important 
step and a goal of future work. Finally, the notion of utilizing non-invasive data 
collected from exfoliated cells in freely voided feces is an exciting prospect for studying 
not ony NSAID enteropathy but a host of other gastrointestinal mucosal diseases. This 
technique could allow us to gain temporal data over time while also collecting data about 
the microbiota. This simultaneous collection of both host data and microbe data could 
begin to allow us to work out the exact mechanisms by which the microbiota influences 
the host response and vice versa. From a clinical stand point this technique is also 
promising as there is clearly potential for determine a set of genes that could be used as a 
screening tool or even diagnostic test for NSAID enteropathy and many other mucosal 
gastrointestinal diseases. While we demonstrated that this technique could successfully 
discriminate between healthy and diseased phenotypes, much work remains in order to 
utilize this technique and a screening or diagnostic tool and that remains an area of 
future work. 
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APPENDIX I 
 
 
Figure A-1.1: Indole attenuates small intestinal mural thickening associated with NSAID 
enteropathy. A) Diagram of location of representative measures for calculating villus 
height [A], crypt depth [B], and mural thickness [C]. Three sets of measurements from 3 
separate sections were recorded for each animal by an observer blinded to treatment 
group. B) Graphical representation of mural thickness among all groups. 
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Figure A-1.2: Co-administration of indole reduces NSAID-induced neutrophilic 
infiltration. A) Representative dot-plots of double-positive CD11b/GR-1 cells 
(neutrophils) from spleen and B) mesenteric lymph nodes. 
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Figure A-1.3: There are no differences in alpha rarefaction among the groups but coverage is adequate. A) Alpha rarefaction 
curves for each treatment group showing numbers of observed species (richness) at each sampling depth on the y-axis and 
sequences/sample on the x-axis up to a sampling depth of 10,800 sequences/sample at Day 0 and B) Day 7. C) Bar charts of 
estimated Good’s coverage at an even sampling depth of 10,800 reads/sample at Day 0 and D) Day 7.  
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Figure A-1.4:  Abundance of critical phyla among the groups at 2 time points: A) 
Abundance of members of the phylum Bacteroidetes in fecal 16S rRNA sequences on 
Day 0 (white bar) and Day 7 (black bar). B)  Abundance of members of the phylum 
Firmicutes in fecal 16S rRNA sequences on Day 0 (white bar) and Day 7 (black bar). 
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Table A-1.1: Pair-wise SIMPER analysis based on the bray Curtis dissimilarity measure 
of fecal 16S rRNA data at the phylum level of each treatment group compared to the 
control group based on day 7 feces. Top panel) The first column identifies the bacterial 
phylum explained by that row, the second column shows % contribution of that phylum 
to the Bray Curtis dissimilarity measure between the 2 groups, the third column tallies 
the cumulative Bray Curtis dissimilarity measure thus far represented in the table, and 
the last 2 columns show mean abundance in control mice and mean abundance for 
NSAID-treated mice, Middle panel) control mice and NSAID + indole-treated mice, and 
Bottom panel) control mice and indole-treated mice. 
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Table A-1.2: Correlation of fecal tryptophan metabolites with histopathology scores < 2 
or > 2. Only the tryptophan metabolite tyramine correlated with microscopic pathology 
score.  
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Figure A-1.5: Co-administration of indole decreased expression of several pro-
inflammatory cytokines and chemokines. A) Log fold-change, and FDR P-value of 
several pro-inflammatory cytokines and chemokines that differed between NSAID vs. 
control (black) and NSAID+Indole vs. control (white).  
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APPENDIX II 
 
 
Figure A-2.1:  Biological variability in the exfoliated IEC data is higher than the tissue 
data but is improved by normalization and is not based on treatment group. A) 
Biological coefficient of variation (BCV) versus the mean log counts per million (CPM) 
of exfoliated IECs after filtering. B) Treatment-based multi-dimensional scaling (MDS) 
plots of exfoliated IEC data after filtering. C) BCV versus CPM of exfoliated IECs after 
filtering and normalization. D) Treatment-based MDS plots of exfoliated IEC data after 
filtering and normalization. E) BCV versus CPM of tissue data after filtering and 
normalization. F) Treatment-based MDS plots of tissue data after filtering and 
normalization. 
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Gene Symbol Error 
MMP13 0 
APAF1 0.0001 
CLUH 0.0001 
HP 0.0006 
NDUFB2 0.0022 
LZTFL1 0.0039 
NLN 0.0054 
SLC47A1 0.0076 
GPX3 0.0087 
SLC35F5 0.01 
MELK 0.01 
MTCH1 0.0119 
SMYD5 0.0119 
SCL11A1 0.0127 
CFL2 0.0127 
GSDMC 0.014 
ARFGEF3 0.0189 
HLA-DQA1 0.0195 
BPTF 0.0209 
G0S2 0.0239 
Table A-2.1: Gene symbol and bolstered re-substituted error rate of the top 20 genes 
identified by one-feature linear discriminate analysis (LDA) that classify NSAID treated 
animals from control animals with less than 5% error. 
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Figure A-2.2: LDA identifies several pathways important in the development of NSAID enteropathy. A) Network of canonical 
pathways, identified by 1-feature LDA. B) Network of canonical pathways to the sets of genes that showed the greatest 
improvement in the estimated error rates when moving from 1-feature to 2-feature LDA. 
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Upstream Regulator P-value of Overlap Target Genes in Dataset 
ARNT2 5.52E-05 
CD86, CFL2, FCGR2A, GPX3, 
OAZ1 
SIM1 6.33E-05 
CD86, CFL2, FCGR2A, GPX3, 
OAZ1 
S100A12 2.12E-04 APAF1, MMP13 
ACTB 5.20E-04 Cald1, SLC11A1 
LTF 7.98E-04 CD86, MMP13 
IL13 9.00E-04 
CD86, FCGR2A, G0S2, GPX3, 
MMP13 
APOE 9.95E-04 CD86, GPX3, MGEA5, MTCH1 
ADAMTS12 1.23E-03 IRG1, MMP13 
MYD88 1.37E-03 CD86, HP, IRG1, LZTFL1 
SOCS1 1.82E-03 CD86, IRG1, MMP13 
 
Table A-2.2: Upstream regulators identified by 1-feature LDA.  Top upstream regulators 
of the genes identified by 1-feature LDA imply importance in the pathophysiology of 
NSAID enteropathy.  Respective P-values of overlap (i.e., overlap of target genes with 
genes in the upstream regulator pathway) and target genes are also shown. 
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Gene 1 Gene 2 2-Feature Error 
RASGEF1B KIAA1217 0 
Dst MSN 0 
TNFRSF21 MSN 0 
RIN2 MAPKAPK2 0 
RIN2 ANXA6 0 
RIN2 ITGB8 0 
RIN2 C1QC 0 
RIN2 SELPLG 0 
RIN2 HLA-A 0 
RIN2 IFI16 0 
RIN2 Gm5150 0 
RIN2 BCL2A1 0 
RIN2 MOB3A 0 
IL15 SMYD5 0 
IL15 CBL 0 
IL15 TTLL7 0 
IL15 HOXB4 0 
IL15 S100PBP 0 
IL15 FOXF1 0 
IL15 C5AR1 0 
 
Table A-2.3: Top 20 gene pairs that accurately classify NSAID from control animals 
Top 20 gene sets and resubstituted error rate of the genes identified by 2-feature LDA 
that classify NSAID treated animals from control animals with less than 5% error. 
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Gene 1 Gene 2 2-Feature Error  1-Feature Error 
QTRT1 HK3 0 >5% 
IFITM1 GNG11 0 >5% 
LCP1 IFITM2 0.0001 >5% 
ASRGL1 GM26698 0.0002 >5% 
GM2848 GM26698 0.0003 >5% 
QTRT1 IFI16 0.0005 >5% 
PARP11 F13A1 0.0005 >5% 
CXCL16 C5AR1 0.0007 >5% 
IFITM1 TBC1D8B 0.0007 >5% 
ST5 MSN 0.0012 >5% 
MSN ANK3 0.0012 >5% 
PTMA MSN 0.0013 >5% 
CXCL16 MSN 0.0014 >5% 
ADH6A IFI16 0.0017 >5% 
Cd52 FAM83B 0.0018 >5% 
PSMA6 MSN 0.0018 >5% 
IFITM1 ALOX5AP 0.0019 >5% 
GM12848 GM1586 0.0019 >5% 
NDUFC2 MSN 0.0021 >5% 
CXCL16 UTP14 0.0022 >5% 
CD52 Klf9 0.0026 >5% 
 
Table A-2.4: 2-Feature LDA reduces error rate and identifies important genes involved 
in NSAID enteropathy. Top 20 gene sets that performed better in combination, in terms 
of reduced error rate, than either gene set alone. 
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Upstream Regulator 
P-Value of 
Overlap 
DYSF 5.47E-05 
IL4 6.37E-05 
TNK1 1.14E-04 
TFEC 1.28E-04 
IL10RA 1.80E-04 
BAK1 3.38E-04 
MGEA5 3.51E-04 
ACKR2 5.51E-04 
PPRC1 8.16E-04 
IFNG 8.84E-04 
ARNT2 9.18E-04 
SIM1 9.98E-04 
BAX 1.09E-03 
TAZ 1.45E-03 
RICTOR 1.85E-03 
 
Table A-2.5: Upstream regulators identified by improved error rate between 1-feature 
and 2-feature LDA.  Upstream regulators were identified using genes that performed 
better in combination, in terms of reduced error rate, as compared to either gene set 
alone. 
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Figure A-2.3: Sparse CCA of the exfoliated IEC transcriptome identifies cytoskeletal 
signaling and inflammatory pathways reflecting NSAID enteropathy. The network of 
pathways to which the genes identified by sparse CCA map are shown.  The darker color 
correlates with lower P-value. 
 
